WO2007011217A2 - Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes - Google Patents
Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes Download PDFInfo
- Publication number
- WO2007011217A2 WO2007011217A2 PCT/NL2006/000383 NL2006000383W WO2007011217A2 WO 2007011217 A2 WO2007011217 A2 WO 2007011217A2 NL 2006000383 W NL2006000383 W NL 2006000383W WO 2007011217 A2 WO2007011217 A2 WO 2007011217A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- targeting
- cell
- complex
- cisuls
- compound
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title claims abstract description 206
- 150000001875 compounds Chemical class 0.000 title claims abstract description 193
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims description 47
- 229910052751 metal Inorganic materials 0.000 title description 33
- 239000002184 metal Substances 0.000 title description 33
- 230000001268 conjugating effect Effects 0.000 title description 3
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 92
- 230000007704 transition Effects 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims description 162
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 134
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 229910052697 platinum Inorganic materials 0.000 claims description 59
- 210000003734 kidney Anatomy 0.000 claims description 56
- 235000018102 proteins Nutrition 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 239000003446 ligand Substances 0.000 claims description 54
- 125000005647 linker group Chemical group 0.000 claims description 53
- 210000004185 liver Anatomy 0.000 claims description 50
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 claims description 47
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 45
- 229960004773 losartan Drugs 0.000 claims description 44
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 44
- 229920001223 polyethylene glycol Polymers 0.000 claims description 34
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 29
- 239000004325 lysozyme Substances 0.000 claims description 29
- 229960000274 lysozyme Drugs 0.000 claims description 29
- 102000016943 Muramidase Human genes 0.000 claims description 27
- 108010014251 Muramidase Proteins 0.000 claims description 27
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 27
- 235000010335 lysozyme Nutrition 0.000 claims description 27
- 238000005859 coupling reaction Methods 0.000 claims description 26
- 238000010168 coupling process Methods 0.000 claims description 25
- -1 TKI Chemical compound 0.000 claims description 24
- 230000008878 coupling Effects 0.000 claims description 24
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 18
- 229950000578 vatalanib Drugs 0.000 claims description 17
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000003019 stabilising effect Effects 0.000 claims description 12
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 11
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- 230000006907 apoptotic process Effects 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 8
- 229960001476 pentoxifylline Drugs 0.000 claims description 8
- 108090001008 Avidin Proteins 0.000 claims description 7
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 7
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 229940043355 kinase inhibitor Drugs 0.000 claims description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 5
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 5
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 2
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 162
- 229940079593 drug Drugs 0.000 description 157
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 117
- 241000700159 Rattus Species 0.000 description 78
- 238000013042 tunel staining Methods 0.000 description 77
- 230000015572 biosynthetic process Effects 0.000 description 64
- 239000000243 solution Substances 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 48
- 239000000047 product Substances 0.000 description 48
- 238000003786 synthesis reaction Methods 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 230000003833 cell viability Effects 0.000 description 45
- 238000011534 incubation Methods 0.000 description 45
- 239000000203 mixture Substances 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 42
- 238000010186 staining Methods 0.000 description 40
- 230000000694 effects Effects 0.000 description 39
- 210000004024 hepatic stellate cell Anatomy 0.000 description 39
- 238000004128 high performance liquid chromatography Methods 0.000 description 38
- 238000011282 treatment Methods 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 238000011156 evaluation Methods 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 102000008100 Human Serum Albumin Human genes 0.000 description 27
- 108091006905 Human Serum Albumin Proteins 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- 210000000056 organ Anatomy 0.000 description 23
- 238000011002 quantification Methods 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 230000003176 fibrotic effect Effects 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000009825 accumulation Methods 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 230000000144 pharmacologic effect Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- 239000000412 dendrimer Substances 0.000 description 16
- 229920000736 dendritic polymer Polymers 0.000 description 16
- 238000004949 mass spectrometry Methods 0.000 description 16
- 241000894007 species Species 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 14
- 229960004316 cisplatin Drugs 0.000 description 14
- 238000009826 distribution Methods 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 239000000969 carrier Substances 0.000 description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 13
- 230000021615 conjugation Effects 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 13
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 12
- 101150065749 Churc1 gene Proteins 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229910002651 NO3 Inorganic materials 0.000 description 12
- 102100038239 Protein Churchill Human genes 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 238000013424 sirius red staining Methods 0.000 description 12
- 125000006850 spacer group Chemical group 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000004294 195Pt NMR spectroscopy Methods 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000000502 dialysis Methods 0.000 description 11
- 239000012467 final product Substances 0.000 description 11
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 238000013425 morphometry Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 150000003057 platinum Chemical class 0.000 description 10
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 102100021947 Survival motor neuron protein Human genes 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000003562 morphometric effect Effects 0.000 description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 239000005864 Sulphur Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000003570 cell viability assay Methods 0.000 description 8
- 208000019425 cirrhosis of liver Diseases 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 7
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 102100039564 Leukosialin Human genes 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011532 immunohistochemical staining Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 7
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229910004679 ONO2 Inorganic materials 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229910021607 Silver chloride Inorganic materials 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000000013 bile duct Anatomy 0.000 description 6
- 229940096422 collagen type i Drugs 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- 210000000651 myofibroblast Anatomy 0.000 description 6
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 5
- 239000007997 Tricine buffer Substances 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 208000004608 Ureteral Obstruction Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229920001427 mPEG Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 235000010344 sodium nitrate Nutrition 0.000 description 5
- 210000004500 stellate cell Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229910052723 transition metal Inorganic materials 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108091058560 IL8 Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 4
- 229930185229 antidesmin Natural products 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 230000009795 fibrotic process Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229920000962 poly(amidoamine) Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 201000002793 renal fibrosis Diseases 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 150000003624 transition metals Chemical class 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 102000047934 Caspase-3/7 Human genes 0.000 description 3
- 108700037887 Caspase-3/7 Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108010008213 RGDPEG-SB-HSA Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 125000003916 ethylene diamine group Chemical group 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229940116357 potassium thiocyanate Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PCZJWSPKNYONIM-VIFPVBQESA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-methylsulfanylbutanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CCSC)C(=O)ON1C(=O)CCC1=O PCZJWSPKNYONIM-VIFPVBQESA-N 0.000 description 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 2
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 108010025752 echistatin Proteins 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- LMABILRJNNFCPG-UHFFFAOYSA-L ethane-1,2-diamine;platinum(2+);dichloride Chemical compound [Cl-].[Cl-].[Pt+2].NCCN LMABILRJNNFCPG-UHFFFAOYSA-L 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- IDNUEBSJWINEMI-UHFFFAOYSA-N ethyl nitrate Chemical compound CCO[N+]([O-])=O IDNUEBSJWINEMI-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000004776 molecular orbital Methods 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 210000005164 penile vein Anatomy 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OIGBULWLGULHNH-UHFFFAOYSA-N tert-butyl n-[2-(2-azidoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN=[N+]=[N-] OIGBULWLGULHNH-UHFFFAOYSA-N 0.000 description 2
- KSFVNEXYCULLEJ-UHFFFAOYSA-N tert-butyl n-[2-(2-hydroxyethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCO KSFVNEXYCULLEJ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NKUZQMZWTZAPSN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-bromoacetate Chemical compound BrCC(=O)ON1C(=O)CCC1=O NKUZQMZWTZAPSN-UHFFFAOYSA-N 0.000 description 1
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QCLUJXAFIBWHOM-UHFFFAOYSA-N 4-[5-(2-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C(=CC=CC=2)F)=C(C=2C=CN=CC=2)N1 QCLUJXAFIBWHOM-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- FQNCLVJEQCJWSU-UHFFFAOYSA-N 6,7-dimethyl-2-phenylquinoxaline Chemical compound N1=C2C=C(C)C(C)=CC2=NC=C1C1=CC=CC=C1 FQNCLVJEQCJWSU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 229940123073 Angiotensin antagonist Drugs 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- FDKIDFYIEWFERB-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;potassium Chemical compound [K].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 FDKIDFYIEWFERB-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000012637 allosteric effector Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- BSJGASKRWFKGMV-UHFFFAOYSA-L ammonia dichloroplatinum(2+) Chemical compound N.N.Cl[Pt+2]Cl BSJGASKRWFKGMV-UHFFFAOYSA-L 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- CWKWIWAIVIEGHP-UHFFFAOYSA-N cyclohexanecarboxamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)C1CCCCC1 CWKWIWAIVIEGHP-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000004537 potential cytotoxicity Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical group C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention is in the field of drug targeting, and relates in particular to the targeting of drugs to selected cell populations and to pharmaceutical compositions comprising cell-targeting moieties.
- Site-specific or targeted delivery of drugs is considered a valuable tool to improve the therapeutic efficacy and to reduce the toxicity of drugs.
- non-targeted drug compounds typically reach their intended target cells via whole-body diffusion and passive diffusion or receptor mediated uptake over the cell membrane
- targeted drugs home-in and concentrate mainly at the targeted tissues. Consequently, targeted drugs require smaller dosages while still allowing the drug to reach therapeutically effective levels inside the target cells.
- the preferred lipophilic character of non-targeted drugs which facilitates their easy passage over the cell membrane and which feature is not always in agreement with other requirements of the drug, is less relevant to targeted drugs.
- the targeting of drugs to specific cells is therefore a conceptually attractive method to enhance specificity, to decrease systemic toxicity and to allow for the therapeutic use of compounds that are in principle less suitable or unsuitable as systemic drugs.
- drug delivery technologies are aimed at altering the interaction of the drug with the in vivo environment and achieve that objective by conjugation of the drug with other molecules, entrapment of the drug within matrices or particles or simply by co-administration with other agents.
- the net result is either drug targeting or enhanced drug transport across biological barriers such that its bioavailability is improved with a reduction of the incidence of clinical side effects in subjects.
- Drug targeting is achieved when an alteration in the drug's bio-distribution favours drug accumulation at the desired site, which site is usually remote from the administration site.
- Cell- selective delivery of drugs can, in principle, be obtained by coupling drug molecules to targeting moieties (macromolecular carriers that contain a chemical moiety that is specifically recognised by target cells in the diseased tissue).
- the present invention provides for an improved coupling of therapeutic compounds to targeting groups.
- the present invention provides a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a (first) reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a (second) reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.
- the metal ion complex is a platinum complex.
- the platinum complex may be a trans- platinum complex or it may be a cis-platinum complex.
- the cis-platinum complex furthermore preferably comprises an inert bidentate moiety as a stabilising bridge.
- the (platinum) metal ion complex comprises a tridentate moiety as stabilising bridge.
- said complex comprises at least two (transition) metal ions, whether or not the same.
- the reactive sites on the targeting moiety and deliverable compound are capable of forming (coordination) bonds with the (transition) metal ion complex.
- the targeting moiety and/or the deliverable compound therefore comprise one or more sulphur-containing reactive sites and/or one or more nitrogen-containing reactive sites.
- the targeting moiety preferably comprises a member of a binding pair.
- the targeting moiety comprises an antibody or parts thereof (e.g. single chain, Fab-fragments), a receptor ligand.
- the binding pairs may be bonded directly to the metal ion complex, or via a spacer or linking molecule.
- a very suitable linking molecule is a macromolecular carrier, preferably HSA or avidin.
- the macromolecular carrier can be bonded directly or indirectly to the metal ion complex, and the macromolecular carrier may further be loaded with members of a binding pair to facilitate targeting of the complex.
- these targeting complexes comprising a macromolecular carrier to which both the metal ion complex- deliverable compound complex and the members of a specific binding pair are bonded will exemplified in the description below.
- the macromolecular carrier comprises additional functionality-providing compounds such as for instance PEG, will become clear from the description and examples.
- the targeting moiety comprises a low molecular weight protein such as for instance lysozyme or any other protein.
- the deliverable compound may in preferred embodiments of the cell- targeting complex of the invention, comprise a protein, more preferably a recombinant protein.
- the (recombinant) protein preferably comprises at least one residue selected from histidine, methionine and cysteine, wherein the methionine and cysteine residue serves as a sulphur-containing reactive site and wherein a histidine residue serves as a nitrogen-containing reactive site.
- the deliverable compound may comprise or be a small molecule, a peptide, a (si)RNA, an anti sense (oligo) nucleotide, or modifications and combinations thereof.
- said protein accumulates in the kidney of a mammal, including a human.
- a particularly preferred embodiment is lysozyme.
- the deliverable compound inhibits a signal transduction cascade in a cellular system, or has antiinflammatory activity, anti-hypertensive activity, antifibrotic activity, anti- angiogenic activity, antitumor activity or apoptosis-inducing activity.
- the deliverable compound is an anti-inflammatory compound, preferably Pentoxifylline or PDTC.
- the deliverable compound is an anti-hypertensive agent, preferably Losartan.
- the deliverable compound is a kinase inhibitor, preferably PTKI, SB202190, PTK787, TKI, Y27632 or AG1295.
- the deliverable protein is a therapeutic protein, more preferably a cytokine or a growth factor.
- the therapeutic protein may be TNF. -related apoptosis-inducing ligand (TRAIL).
- TRAIL apoptosis-inducing ligand
- the protein may be IL-IO, alkaline phosphatase, superoxide dismutase, immunoglobulins or parts thereof (e.g. single chain, Fab-fragments or whole IgG), lactoferrin, xanthine oxidase, or TNF ⁇ .
- the present invention provides a pharmaceutical composition comprising a cell-targeting complex as described herein, and a pharmaceutically acceptable formulation for the intended application.
- the present invention provides a cell-targeting complex as described above, for use as a medicament.
- the present invention provides the use of a (transition) metal ion complex capable of forming coordination bonds, for linking a targeting moiety to a deliverable compound.
- the metal ion complex is a platinum complex.
- the platinum complex may be a trans -platinum complex or it may be a cis-platinum complex.
- these platinum complexes preferably comprise an inert bidentate or tridentate moiety as a stabilising bridge.
- the targeting moiety and therapeutic compound may comprise one or more sulphur- containing reactive sites and/or one or more nitrogen containing reactive-sites for participating in the coordination bond.
- Metal ion complexes of the present invention contain at least one (transition) metal ion.
- the metal ion complex comprises two or more transition metals for binding a targeting moiety to a therapeutic compound. This embodiment is of course also a part of the targeting complex aspect described above.
- the invention provides for the referred use wherein said deliverable compound is a diagnostic compound or therapeutic compound, preferably a therapeutic compound as the (transition) metal ion complex provides release functionality.
- therapeutic compounds that inhibit a signal transduction cascade in a cellular system, or that have anti-inflammatory, anti-hypertensive, antifibrotic, anti-angiogenic, antitumor or apoptosis- inducing activity.
- Preferred compounds are, as stated earlier herein, kinase inhibitors or apoptosis inducing compounds.
- therapeutic compound is pentoxifylline, PDTC, Losartan, PTKI, SB202190, PTK787, TKI, Y27632, AG1295 or TRAIL
- Highly preferred targeting moieties for application in the use of the present invention are mannose-6-phosphate modified human serum albumin or RGD- loaded albumin, PEGylated albumin, a low molecular weight protein, an Ab or an Ab fragment or a polymer or a modified polymer.
- the present invention provides a method of coupling a targeting moiety to a therapeutic compound comprising a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said therapeutic compound and allowing said (transition) metal ion complex to form coordination bonds with said targeting moiety and said therapeutic compound.
- Preferred embodiments of this aspect of the invention include those embodiments as described for the cell-targeting complex and the use of the invention as described above.
- the present invention provides a method of targeting therapeutic compounds to selected cell populations, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition according to the present invention.
- Figure 1 shows the reaction scheme of the modified [Pt(ethylenediamine)dichloride] systems trans-
- FIG. 3 shows the synthetic scheme for the preparation of the dinuclear conjugate 4.
- Figure 4 shows drug release profiles of cell targeting complexes.
- FIG. 5 Incubation of HSC with PTX-cisULS-M6PHSA for 24h, followed by immunohistochemical staining for fibrosis markers.
- Activated HSC express collagen type I in a granular staining pattern in the cytoplasm, probably reflecting the presence of procollagen type I, while ⁇ SMA stained in a fibre-like pattern.
- Treatment with PTX in a concentration of 1 mM reduced the red coloured intensity of both fibrotic markers.
- FIG. 1 Effects of PTKI-cisULS-M6PHSA on gene-expression in HSC (panel A) or liver slices from fibrotic rat livers (panel B). See Example 2.2 for details.
- FIG. 7 Effect of RGD-PEG-SB202190-cisULS-HSA on gene- expression in endothelial cells. TNF-activated HUVEC were incubated with indicated compounds. Panel A: gene-expression analysis; panel B: determination of IL-8 in culture medium. See Example 2.2 for details.
- FIG. 8 Effects of SB-cisULS-LZM (panel A) and TKI-cisULS-LZM (panel B) on the gene expressions of procollagen-Ial induced by TGF- ⁇ l in HK- 2 renal tubular cells. See Example 2.2 for details.
- FIG. 9 Effects of RGD-equipped TK787-albumin conjugates on gene-expression in endothelial cells.
- VEGF-activated HUVEC were incubated with indicated compounds. See Example 2.2 for details.
- Figure 10 Incubation of HSC with cell targeting complexes.
- A-D PTX-cisULS-M6PHSA; A: cell viability; B: caspase 3/7 activity; C: TUNEL staining; D: quantification of TUNEL positive nuclei (TUNEL/DAPI ratio).
- E losartan-cisULS-M6PHSA, cell viability assay; F: PTKI-cisULS-M6PHSA, cell viability assay. See Example 2.3 for details.
- Figure 11 Incubation of NRK-52E cells with cell targeting complexes and comparison of cellular toxicity with other compounds.
- Figure 13 Incubation of HUVEC with non-modified hisTRAIL and biotinylated TRAIL (panel A) or RGD-equipped TRAIL (panel B) for 48h, followed by MTS cell viability assay. See Example 2.3 for details.
- Figure 14 Incubation of Jurkat T-cells with cell targeting complexes. A 5 C: cell viability assay after 48h of incubation; B,D: caspase activity assay after 4h incubation. See Example 2.3 for details.
- FIG. 15 A: Binding of PTX-cisULS-M6PHSA to fibroblasts.
- Cells incubated with PTX-cisULS-M6PHSA showed intensely red staining of cell-associated or internalized conjugate, not observed after incubation with PTX-cisULS-HSA. See Example 2.4 for details.
- FIG. 16 Binding of cell targeting complexes to endothelial cells: SB202190-cisULS equipped complexes. Cell-associated radioactivity after incubation with radiolabeled RGDPEG-SB202190-cisULS-HSA. A: incubation at 4°C for 4h; B: incubation at different temperatures and different duration. See Example 2.4 for details.
- FIG. 1 Binding of cell targeting complexes to endothelial cells. Binding affinity was determined by competitive displacement of radiolabeled echistatin. A-D: incubation with RGD-equipped PTK787-cisULS complexes; E: incubation with RGDPEG-avidin. See Example 2.4 for details.
- FIG. 18 Pharmacokinetics of PTX-cisULS-M6PHSA in BDL3 rats. Organ distributions were determined in BDL rats at 10 min administration of the compounds. See Example 3.1.1 for details.
- Figure 19 Organ distribution of losartan-cisULS-M6PHSA in BDL rats. Anti-HSA staining of lung (a), spleen (b), heart (c), kidney (d), liver (e). anti-HSA and anti-desmin double staining in liver (f, g). Red color of HSA staining was not detected in lung, spleen, heart or kidney, while it was detected in the liver within the non-parenchymal cells of rats treated with losartan-cisULS-M6PHSA (magnification 4x).
- Losartan-M ⁇ PHSA co-localized with stellate cells in rat livers, as assessed with double immunostaining with anti-HSA and anti-desmin (arrows in f,g; magnification 4Ox).
- B losartan tissue levels in the livers of CCL4 rats. See Example 3.1.1 for details.
- Figure 20 Pharmacokinetic evaluation of SB202190-cisULS-LZM.
- A,B SB202190 levels in serum (A) or kidney (B).
- C anti-LZM staining in kidney sections, arrows indicate accumulation of conjugate (red color) in tubular cells. See Example 3.1.2 for details.
- FIG. 21 Pharmacokinetic evaluation of TKI-cisULS-LZM.
- A-C TKI levels in serum (A) or kidney (B) or urine (C).
- D anti-LZM staining in kidney sections, arrows indicate accumulation of conjugate (red color) in tubular cells. See Example 3.1.2 for details.
- Figure 22 Pharmacokinetic evaluation of Y27632-cisULS-LZM. See Example 3.1.2 for details.
- Figure 23 Pharmacological evaluation of losartan-cisULS-M6PHSA in BDL rats.
- A-D Sirius Red staining for collagen in fibrotic liver. Severe bridging of collagen (red color) was observed in rats receiving saline (A), M6PHSA (B) and oral losartan (D). However, rats treated with losartan- M6PHSA (C) showed fewer areas with collagen accumulation.
- E morphometric quantification of Sirius Red staining.
- F gene-expression analysis of procollagen ⁇ l. See Example 3.2.1 for details.
- FIG. 24 Pharmacological evaluation of losartan-cisULS-M6PHSA in CCU rats.
- A-D Sirius Red staining for collagen in fibrotic liver. Red color indicates the deposition of collagen in the liver, which was markedly reduced after treatment with losartan-cisULS-M6PHSA but not after M6PHSA or free losartan.
- E morphometric quantification of Sirius Red staining. See Example 3.2.1 for details.
- Figure 25 Pharmacological evaluation of losartan-cisULS-M6PHSA in fibrotic rats.
- A-D staining for ⁇ SMA in fibrotic livers of BDL rats.
- E High magnification photomicrograph of a saline treated BDL rat. Arrows denote SMA in activated HSC-derived (upper) or myofibroblasts surrounding proliferating bile ducts (lower arrow).
- F morphometric quantification of SMA staining in BDL rats.
- G,H staining for ⁇ SMA in fibrotic livers of CCL4 rats.
- Treatment with losartan-cisULS-M6PHSA reduced the intensity of staining (reduction in brown color).
- I morphometric quantification of SMA staining in CCL4 rats.
- FIG. 26 Pharmacological evaluation of losartan-cisULS-M6PHSA in BDL rats.
- A-D CD43 staining for infiltrated immune cells in fibrotic liver. Rats receiving saline (A) or M6PHSA (B) showed intense infiltration by CD43- positive cells (brown color).
- E morphometric quantification of CD43 staining of the number of positive cells in 20 randomly chosen high power fields. See Example 3.2.1 for details.
- FIG 27 Pharmacological evaluation of PTKI-cisULS-M6PHSA in BDL rats.
- A morphometric quantification of Sirius Red staining for in fibrotic liver.
- B photomicrographs of Sirius red staining of livers 1 day after administration of compounds (BDLlI) or 2 days after administration (BDL12).
- Treatment with PTKI-cisULS-M6PHSA reduced the brown-reddish color of stained collagen at both time points, and also reduced the bridging between collagen-rich areas. See Example 3.2.1 for details.
- Figure 28 Pharmacological evaluation of PTKI-cisULS-M6PHSA in BDL rats.
- A morphometric quantification of Sirius Red staining for in fibrotic liver.
- B photomicrographs of Sirius red staining of livers 1 day after administration of compounds (BDLlI) or 2 days after administration (BDL12).
- Treatment with PTKI-cisULS-M6PHSA reduced the brown-reddish color
- BDL rats BDL rats.
- A morphometric quantification of ⁇ SMA staining for in fibrotic liver.
- B photomicrographs of ⁇ SMA staining (brown color) of livers 1 day after administration of compounds (BDLlI) or 2 days after administration (BDL12).
- Treatment with PTKI-cisULS-M6PHSA reduced the brown-reddish color of stained SMA at both time points. See Example 3.2.1 for details.
- FIG. 29 Pharmacological evaluation of SB202190-cisULS-LZM in I/R rats.
- A-C staining for phosphorylated p38 in control I/R rats (A), SB202190-cisULS-LZM treated I/R rats (B) or SB202190 treated I/R rats (C).
- D-F staining for ⁇ SMA in control I/R rats (D), SB202190-cisULS-LZM treated I/R rats (E) or SB202190 treated I/R rats (F).
- Arrows in panels A-C indicate the immunolocalization (dark brown color) of p-p38 positive nuclei in the tubular cells corresponding to the dilated and injured tubules.
- FIG. 1 Shows in panels D-F indicate the localization of ⁇ SMA (red color) in tubulointerstitial space.
- Treatment with SB202190-cisULS-LZM reduced the number of p-p38 positive cells and the expression of ⁇ SMA as compared to I/R controls, while free SB202190 did not affect either parameter. See Example 3.2.2 for details.
- Figure 30 Pharmacological evaluation of losartan-cisULS-LZM in I/R rats. Infiltrated immune cells in the kidney were detected by EDl staining and counted by two independent observers. See Example 3.2.2 for details.
- Figure 31 Pharmacological evaluation of Y27632-cisULS-LZM in I/R rats.
- Renal gene expression levels were determined by qRT-PGR and expressed relative to the levels of control I/R animals. See Example 3.2.2 for details.
- Figure 31 A presents the gene expression levels in the kidney.
- vehicle-treated I/R animals had a significant increase in the gene expression of the inflammation marker MCP-I and of fibrosis markers ⁇ -SMA, TGF- ⁇ l, procollagen-I ⁇ l and TIMP-I.
- Data represents mean ⁇ SEM.
- ffp ⁇ .01 andfftp ⁇ 0.001 represent the difference versus normal rats. Other differences are indicated as *p ⁇ 0.05 and ** p ⁇ 0.01.
- UUO rats A: Relative gene expression in the kidney of MCP-I; B: quantification of renally infiltrated macrophages; C: quantification of SMA staining in the kidney. See Example 3.2.2 for details.
- Figure 33 shows one possible configuration of a complex according to the present invention for the targeting of PTK787 as a deliverable compound.
- RGD as anexample of the homing part of the targeting moiety, may be coupled in various ways to the drug PTK787.
- PTK787 is coupled directly to the metal ion complex, whereas the cyclic RGD may be bonded to the metal ion complex via a carrier protein (HSA) or still further via an additional PEG-linker.
- HSA carrier protein
- the advantage of using HSA is that this protein is not foreign to human subjects, and thus does not exert an immune response.
- Figure 34 shows another possible configuration of a complex of the present invention for the targeting of a therapeutic compound (indicated is TRAIL).
- A is the carrier/homing protein (for instance avidin, which has a high affinity for biotin and a high RGD loading capacity);
- B is a versatile linker (for instance polyethylene glycol, serving as a bivalent linker for RGD conjugation, serving to prolong circulation time (avoiding non-target cell binding) and shielding the modified carrier (e.g from macrophage clearance));
- C is the homing molecule (for instance c(RGDf), which displays high affinity binding to ⁇ v ⁇ 3 integrin-expressing cells (endothelial cells in newly formed blood vessels));
- D is the deliverable compound (for instance the therapeutic protein human recombinant TRAIL, which induces selective apoptosis in tumor cells));
- E is a histidine tag suitable for purification purposes and coupling to the (transition) metal ion complex (e.g.
- F is a bio-linker (consisting of for instance a sulfo-NHS biotin part for direct coupling to a lysin residue, and a ULS biotin part, the platinum-based linker for drug conjugation)
- targeting moiety refers to any molecule or complex that can redirect, modify or improve the pharmacokinetic properties of a drug or other type of deliverable compound.
- the targeting moiety comprises a compound or part of a molecule which functionally interacts with a binding site on the surface of the cell, also indicated with the term " homing part".
- the targeting moiety through the presence of homing part provides specificity for or binding affinity for one or more cell types.
- the targeting moiety may consist of a homing part. In such an embodiment, for instance an antibody, hapten or teceptor ligand is bonded directly to the metal ion complex.
- the molecule on the cell which is targeted by the targeting moiety can be any suitable target, such as for instance a cell surface receptor.
- Targeting moieties may include such homing parts as, but are not limited to, antibodies, antibody fragments, endogenous or non- endogenous ligands for a cell-surface receptor, antigen- binding proteins, viral surface components, proteins, for instance those that bind viral surface components, growth factors, lectins, carbohydrates, fatty acids or other hydrophobic substituents, peptides and peptidomimetic molecules.
- Targeting moieties may either encompass complexes (see for instance RGD-HSA, RGD-HSA-PEG and RGDPEG-HSA in Fig 33, wherein the homing part is complexed with macromolecules to yield, multivalent structures) or may comprise or consist of a small molecule in the form of an antibody fragment or a small protein or peptide, such as for instance lysozyme.
- the targeting moiety may be a complex comprising a central macromolecular core as a carrier, to which one or more homing molecules are attached and optionally one or more functional groups which modify the functionality of the carrier.
- a very suitable example is that displayed in Figure 34, wherein the macromolecule avidin is used to increase the capacity of the complex for loading with the specific homing molecule RGD.
- the homing molecule may be coupled via a versatile linker, such as a PEG linker.
- Suitable macromolecular carrier compounds may thus for instance be avidin, human serum albumin (HSA) or dendrimers such as but not limited to PAMAM, or derivatives thereof.
- Preferred macromolecular carrier compounds in targeting moieties used in the present invention are Human Serum Albumin (HSA) or derivatives thereof, Since these are non- foreign to the human body.
- HSA Human Serum Albumin
- derivatives thereof in this context refers to macromolecular carrier compounds modified by attachment thereto of a homing molecule (e.g. RGD or M6P).
- a homing molecule e.g. RGD or M6P
- Mannose 6 phosphate derivatised macromolecular carriers allow for the targeting of a deliverable compound to for instance the liver, in particular the stellate cell receptors of necrotized liver tissue).
- HSA can suitably be used as a core protein, which may be substituted with polyethyleneglycol (PEG) groups, which infer stealth properties in the final construct.
- PEG polyethyleneglycol
- these PEG ligands can prevent the uptake by non-target cell such as macrophages.
- the targeting moiety does not bind to target receptors, but affects the body distribution by altering the clearance route or rate of the deliverable compound via other principles.
- This class of targeting moieties includes, but is not limited to, polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- Another non-limiting example of such a type of targeting moiety is a polymeric biomaterial which functions as depot that is releasing the coupled deliverable compound.
- Such a device may circulate in the blood stream or may be implanted in another part of the body, for instance subcutaneously. All above mentioned structures are collectively and individually called targeting moieties.
- the term "deliverable compound” as used herein refers to a compound which is carried or transported by the targeting moiety to the surface and/or interior of a cell.
- the deliverable compound is a therapeutic or diagnostic compound.
- the terms "deliverable compound” and “therapeutic compound” and “drug” are used interchangeably herein and represent any agent that can be applied for therapeutic or diagnostic use.
- the therapeutic compound may be a prodrug, which requires (bio)chemical modification to reach its active form.
- the therapeutic compound is an organic molecule that contains an aromatic nitrogen or a sulphur atom which can form a coordination bond with the linker.
- the therapeutic compound may also contain a prodrug moiety that contains an aromatic nitrogen or a sulphur atom which can form a coordination bond with the linker.
- the therapeutic compound is a therapeutically active peptide or protein.
- the thereapeutic compound may be a small molecule, a peptide, a (si)RNA, an anti sense (oligo) nucleotide, or modifications and combinations thereof.
- reactive moiety refers to a chemical group, a free orbital reactive site or a ligand of the metal ion complex or compound that is capable of forming a bond with a reactive site of either a targeting moiety or a deliverable compound.
- ligands refers to a molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, or ligand binding to a receptor, or a substrate or allosteric effector binding to an enzyme.
- ligand is also used to indicate molecules that donate or accept a pair of electrons to form a coordinate bond with the central metal atom of a coordination complex. Thus meaning of the term ligand is context- related.
- (transition) metal ion complex refers to the linker system used to couple the targeting moiety to the deliverable compound.
- Metal ions suitable for use in a (transition) metal ion complex used in the present invention are metal ions capable of forming coordination bonds with ligands.
- transition metals such as Pt, Eu, Cu, Zn, Ni, Pd, Os and Cd are amenable for use in the present invention.
- the (transition) metal ion complex of the present invention consists of a central metal ion bound to a number of other molecules, termed ligands.
- the nature of the chemical bond formed between ligand and metal can be thought of as involving the donation of a pair of electrons present on the ligand molecule or, in molecular orbital terms, as a molecular orbital formed by combining a filled orbital of the ligand with a vacant orbital of the metal.
- Those atoms in the ligand molecule that are directly involved in forming a chemical bond to the metal ion are therefore termed the donor atoms, generally comprising elements of Groups V and VI of the periodic table, with nitrogen, oxygen, sulfur, phosphorus and arsenic being those most commonly employed.
- chelating agents Molecules that contain two or more donor atoms capable of binding to a single metal ion are termed chelating agents, or chelators, and the corresponding metal complexes are called chelates.
- the number of donor atoms present in a given chelator is termed the denticity of that chelator, ligands possessing two donor sites being called bidentate, those with three donor sites, tridentate, and so forth.
- the maximum coordination number of a given metal ion in a given oxidation state is an intrinsic property of that metal, reflecting the number of vacant orbitals and, hence, the number of chemical bonds it is able to form with ligand donor atoms.
- the metal is said to be coordinatively saturated.
- a chelator can be a targeting moiety, deliverable compound, or stabilising bridge.
- pyrrolidine dithiocarbaniate PDTC
- useful ligands according to the present invention may be selected by one skilled in the art, employing the following criteria. Ligands must possess donor atoms (or sets of donor atoms in the case of chelating ligands) that favor binding to the target metal ion.
- any given metal ion for particular donor atoms (generally selected from the group consisting of carboxylic, phenolic, or ether oxygen atoms, amine, imine, or aromatic nitrogen atoms and charged or neutral sulfur atoms) is well known in the art.
- the ligands must also offer the prospect of forming ligand-metal linkages that are likely to display appropriate stability in vivo. That is, the ligand-metal linkage does not dissociate during the time required to transport the therapeutic compound to the target cell. In addition, but depending on the intended application for any given deliverable compound, the ligand-metal linkage must offer the prospect of drug-release inside the target cell or at the target site. For many metals of interest there exists considerable art relating to the in vivo stability of particular ligand-metal linkages, which may be used to guide ligand-metal selection.
- ligands that have been shown to coordinately bond to metal ions; they may either be mono, bi, or tridentate, depending on the number of sites that the ligand binds to the metal ion.
- the above described ligands may be bifunctional.
- a bifunctional ligand is a molecule that contains, in addition to at least one metal binding site (donor atom), a second reactive moiety through which the ligand may be linked to, for example, a protein, without significantly affecting the metal-binding properties of the ligand.
- the present invention provides for a novel type of linker system or linker in which the deliverable compound is joined by means of one or more coordination bonds with the targeting moiety.
- the existing (co ⁇ alent) linkage methods are insufficient to prepare a cell targeting complex with appropriate stability of the drug-carrier linkage in vivo as described above.
- the linkage system is very important and should provide for bonding that prevents premature release of the drug from the carrier in the circulation, while not being too stable, so that the drug remains inactive even when accumulated at/or in the target site.
- the application of a novel linker technology as described in the present invention creates the opportunity to couple drug molecules via one or more coordination bonds with the (transition) metal complex.
- One major advantage of the described linker system is that it allows for the development of cell targeting complexes with drugs that could not be produced previously due to the lack of coupling technology.
- the bond may be reversed, especially when small electron rich materials are present, e.g. in vivo gluthathione, in vitro potassium thiocyanate.
- small electron rich materials e.g. in vivo gluthathione, in vitro potassium thiocyanate.
- the structure of the deliverable compound is not affected or changed upon binding and release.
- therapeutic proteins such as antiinflammatory cytokines
- targeting moieties often causes the formation of undefined complexes of variable size and composition.
- this problem originates from the chemistry applied in the conjugation of the targeting moiety to the therapeutic protein.
- Many covalent linkers are directed to reactive sites like terminal amino groups of lysyl residues that are abundantly present within the protein.
- a linker system that reacts at more specific locations in the protein, as defined by the distribution of cysteine, methione and/or histidine residues within the protein, will yield better defined cell targeting complexes.
- the cell targeting complex has been prepared by reacting a recombinant protein displaying a "methionine start codon” or a "histidine tag” sequence, or a combination of these sequences, that both can react with the transition metal linker.
- a cell-targeting complex of the present invention may have various forms or constitutions wherein the targeting moiety and a therapeutic compound are joined by means of a (transition) metal ion containing linker system.
- a (transition) metal ion containing linker system In (transition) metal ion complexes, platinum is the preferred metal ion.
- a cell-targeting complex of the invention may be represented by the formula:
- - DC is the deliverable compound
- TM is the targeting moiety
- M is a (transition) metal ion linker system.
- the deliverable compound and the targeting moiety may be coupled directly to the (transition) metal ion linker system by means of a coordination bond.
- the deliverable compound or the targeting moiety may be coupled to an inert multiple dentate moiety or stabilising bridge in a metal ion complex.
- the deliverable compound or targeting moiety may be coupled to the ethylenediamine stabilising bridge of a c ⁇ s-platinum complex.
- the (transition) metal atom then functions as a reactive moiety for coupling to the targeting moiety or deliverable compound only, and not (directly) to the deliverable compound or targeting moiety, respectively.
- a cell-targeting complex of the present invention may comprise a spacer between the linker and the deliverable compound and/or targeting moiety.
- Such a cell-targeting complex may be represented by the formula:
- DC, TM and M are as defined above, and - Xi is an optional spacer group or prodrug coupled to the (transition) metal atom by means of a coordination bond, and wherein Xi is coupled by other chemical bonding (e.g. by covalent bond) to the deliverable compound.
- Xi may very suitably be a spacer comprising a (transition) metal or a (enzyme responsive) cleavage site to allow for release of the therapeutic compound from the metal ion complex, and
- X2 is an optional spacer group between the metal atom and the targeting moiety.
- X2 may very suitably be a spacer comprising a (transition) metal or a (enzyme responsive) cleavage site to allow for release of the deliverable compound and metal ion complex from the targeting moiety.
- at least one of Xi or X2 is present.
- both Xi and X 2 are present.
- Suitable types of spacer groups are molecules that allow for an appropriate distance between the metal ion complex and another functional group and also allow further modification of the linker complex.
- Preferred linkers are [NH2-(CH2)n-NH2] wherein n varies between 1 and 10, preferably between 1 and 6.
- the spacer diaminohexane [NH2-(CH2)6-NH2] has been proven very useful in preferred embodiments of this invention.
- Other preferred linkers are [NH2-(CH2)n-A-(CH2) n -NH2] wherein A is a heteroatom, preferable N or O, and n varying between 1 and 5.
- spacer is NH 2 -(CH 2 )n-NHR wherein n can be any number between 1 and 6, and R may be independently chosen to be C(O)CH 2 Br, CO-(CH 2 )In-(C 4 H 2 NO 2 ) wherein m is 1 - 10 preferentially 5, CO-(C 6 HiO)-CH 2 -(C 4 H 2 NO 2 ), or CO- (CH 2 )2-NH 2 -CO-CH 2 -Br.
- spacer is NH 2 -(CH 2 )n-NH- CO-(CH2)n-mPEG wherein n varies between 1 and 6 and mPEG represents polyethylene glycol whether or not having -(C4H2NO2) bond thereto.
- the linker may be attached to - or being part of - the stabilizing bridge of the (transition) metal ion complex.
- Preferred structures are — (CH 2 )n- NHR wherein n can be any number varying from 1 to 10, preferentially 6, and R may be independently chosen to be C(O)CH 2 Br, CO-(CH 2 )In-(C 4 H 2 NO 2 ) wherein m is 1 - 10 preferentially 5, CO-(C 6 HiO)-CH 2 -(C 4 H 2 NO 2 ), CO-(CH 2 ) 2 - NH 2 -CO-CH 2 -Br, or -CO-(CH 2 ) n -mPEG wherein n varies between 1 and 6 and mPEG represents polyethylene glycol whether or not having -(C 4 H 2 NO 2 ) bond thereto.
- a cell-targeting complex of the present invention may comprise more then one (transition) metal ion linker system.
- a (transition) metal ion complex that contains two (transition) metal ions is referred to as a dinuclear species.
- a dinuclear species may be represented by the formula:
- Mi and M2 are (transition) metal ion linkers as defined above;
- A is an aliphatic chain whether or not containing a heteroatom.
- a therapeutic compound or targeting moiety linked to a platinum complex may be referred to as a Pt-S adduct (when attached to a sulphur containing reactive site), to a Pt-N adduct (when attached to a nitrogen containing reactive site), or in general to a Pt-adduct.
- a sulphur containing reactive site may hereafter be referred to as a S-reactive site, and a nitrogen containing reactive site may hereafter be referred to as N-reactive site.
- Platinum complexes may react with a variety of reactive moieties on biomolecules and various types of detectable marker moieties are known to have been adhered to ionic platinum.
- Cis-platinum complexes are suitable for linking labels to several kinds of bio-organic molecules, such as peptides, polypeptides, proteins, and nucleic acids. Methods using trans- platinum complexes have also been reported (EP 0 870 770) as suitable for labeling a variety of bio-organic molecules and linking of labels thereto.
- the present inventors have found that a particular advantage of the use of a (transition) metal ion complex as a linker between a deliverable compound and a targeting moiety in targeted drugs is that (transition) metal ion complexes provide for bonds that are strong enough to allow the deliverable compound to be transported to various tissues in vivo while remaining coupled to a targeting moiety.
- the reactivity of platinum complexes towards a variety of reactive sites in drug molecules is a benefit in the application as a drug linking system, since it allows straightforward conjugation reactions that result in quantitative yields of the desired products.
- a further advantage of the use of (transition) metal ion complexes is that, depending on the reactive moieties used, such complexes may support the coupling of a wide variety of biologically active compounds to targeting molecules, whereby the chemistry of the targeting moieties as well as of the therapeutic compounds can vary greatly.
- targeting moieties or deliverable compounds may be linked via a suitable (transition) metal ion complex at histidine (His), methionine (Met) and/or cysteine (Cys) residues within protein or peptide chains.
- His histidine
- Met methionine
- Cys cysteine residues within protein or peptide chains.
- This provides for the possibility to link to different and multiple side groups in a protein or peptide chain, which may for instance allow for the linking of several deliverable compounds to one targeting moiety or vice versa.
- the linkage of drugs or targeting moiety groups via the metal ion complex to these amino acid residues will allow concomitant derivatization of lysine side chains by a conventional derivatization strategy, without interference of the two reactions.
- the coupling of either substituent to the core protein or peptide will not lower the reaction efficiency, as is observed in conventional strategies that aim at lysine residues with both types of reactions.
- the specificity of the coupling reaction with (transition) metal ion complexes may be controlled such as to discriminate between coupling to sulphur containing reactive sites and nitrogen containing reactive sites in a targeting moiety or deliverable compound. Therefore, by using the (transition) metal ion linker according to the present invention one can direct the coupling of a targeting moiety or deliverable compound towards a specified reactive site within a targeting moiety or deliverable compound.
- Platinum is a preferred metal ion in (transition) metal ion complexes.
- preferred platinum complexes suitable for use in a method of the present invention are cis- or trans -platinum complexes of the formula [Pt(II) (Xs)(X4) (T) (D)] or a c ⁇ s-platinum complex of the formula [Pt(II)(X 5 )(T)(D)].
- Pt represents platinum (Pt)
- T and D represent the same or different reactive moieties, that participate in the reaction with a targeting moiety (T) or a deliverable compound (D), respectively.
- the substituents at position T and D will be replaced by another ligand to form the complex with targeting moiety or a deliverable compound.
- the entities, X3 and X4 represent the same or different inert moieties, and X5 represents an inert moiety that may act as a stabilising bridge such as a multiple dentate ligand, e.g. a bidentate ligand.
- a preferred group of bidentate ligands are aliphatic diamine bridges and diamine cyclo bridges, all sufficiently known by persons skilled in the art. An overview of preferred tridentates is given in patent application EP 04078328.4 which are incorporated herein by reference.
- a platinum(II) complex for use in a method of the invention can be prepared via any method known in the art. References can for example be found in Reedijk et ⁇ l. (Structure and Bonding, 67, pp. 53-89, 1987). The preparation of some trans- platinum complexes is disclosed in EP 0 870 770. Further preparation methods can be found in WO 96/35696 and WO 98/15564. Methods described in any of these publications are incorporated herein by reference.
- platinum complexes are prepared according to the spacer - tert butoxycarbonyl / NHS - pathway. In this approach, one of the ligands at the metal ion consists of a spacer molecule that contains an amino group distant from the metal ion that can be further derivatized for the purpose of conjugating either deliverable compound or targeting moiety.
- Reactive moieties (T D) of a platinum complex that will be replaced by targeting moiety and deliverable compound are preferably good leaving ligands.
- a platinum complex, wherein T and/or D are independently chosen from the group of Cl “ , NO 3 " , HCO 3 “ , CO 3 2" , SO 3 2" , ZSO 3 “ , I “ , Br “ , F “ , acetate, carboxylate, phosphate, ethylnitrate, oxalate, citrate, a phosphonate, ZO % and water has been found to be particularly suitable for use in a method according to the invention.
- Z is defined herein as a hydrogen moiety or an alkyl or aryl group having from 1 to 10 carbon atoms. Of these ligands, Cl “ and NO 3 " are most preferred.
- inert moiety Xs may be chosen.
- Inert as used herein indicates that the moiety remains attached to the platinum complex during the linking process.
- a platinum complex comprising one or two inert moieties chosen from the group of NH3, NH2R, NHRR', NRR'R" groups, wherein R, R' and R" preferably represent an alkyl group having from 1 to 6 carbon atoms has been found to be particularly suitable for use in a method of the present invention.
- H2NCH3 is a particularly preferred inert moiety.
- An alkyl diamine, wherein the alkylgroup has 2 to 6 carbon atoms is a preferred bidentate inert moiety in a cis-platinum complex (e.g. X5 in formula Ic).
- X5 represents ethylene diamine.
- platinum complexes for use in a method of the present invention include cis[Pt(en)Cl2], cis[Pt(en) Cl(NOa)], cis[Pt(en)(NO3)2], trans[Pt(NH 3 )2Cl 2 ], trans [Pt(NHs) 2 Cl(NO 3 )], and trans [Pt(NHs) 2 (NOa) 2 ]; in these formulas, en indicates an ethylenediamine moiety.
- any type of reactive site of a targeting moiety or deliverable compound may be used as coupling site in a method of the invention.
- Preferred nitrogen containing reactive sites include reactive sites comprising a primary amine, a secondary amine, a tertiary amine, an aromatic amine, an amide, an imide, an imine, an iminoether, or an azide.
- Preferred sulphur containing reactive sites include reactive sites comprising a thiol, a thioether, a sulfide, a disulfide, a thioamide, a thion, a dithiocarbamate.
- Proteinaceous deliverable compounds and targeting moieties may be facilitated with (enzyme responsive) cleavage sites by using recombinant protein technology.
- the drug release facility is included in the linkage system.
- the cleavage site is degradable by enzymes that are specifically present within the target area (metalloproteinases, plasmin or lysosomal proteases). In this way, additional site-specificity is created to cause release of pharmacologically active compounds only in or at the target site.
- the deliverable compound may be any compound exerting therapeutic effect or having a diagnostic purpose.
- Non-limiting examples of deliverable compounds amenable for use in the present invention may be either proteinaceous macromolecules, or smaller chemical or nature-derived drug molecules.
- the therapeutic compound may for instance be a bioactive protein.
- Molecular biology has realised the possibility to design and produce recombinant proteins that can be used as a drug.
- proteins like for instance cytokines and growth factors, are mediators with potent biological. activities.
- therapeutic applications of cytokines are often limited because of the following considerations. Firstly, these potent mediators generally display multiple biological activities, that can also be harmful to the subject.
- the coupling of the deliverable to a targeting moiety improve the selectivity for an organ, tissue or cell type of the compound, and thereby greatly improve its therapeutic profile.
- the plasma half-life of cytokines and many other recombinant proteins is generally short because of rapid elimination.
- the coupling of a targeting moiety to the therapeutic compound may improve the pharmacokinetic properties of the compound.
- targeted delivery of recombinant proteins may allow the usage of lower doses, which can facilitate the successful application of therapeutic proteins that are produced in low yield.
- Successful drug targeting strategies may therefore open the application of a spectrum of therapeutic proteins.
- Bio-active proteins and small drugs may in principle be coupled to a targeting moiety via a stable bond that is resistant to degradation, or by a bond that is cleaved within or outside the target cell resulting in the release of the pharmacological active compound from the carrier.
- the present invention allows for both types of bonds, for instance through modification of the coordination (platinum) compounds.
- the present invention relates to complexes wherein the targeting moiety is bonded to the deliverable compound via a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound.
- the (transition) metal ion complex (for instance the ULS linker as presented herein) provides for a slow release of the deliverable compound from the targeting moiety.
- the therapeutic compound is slowly released over a prolonged period of time, for instance multiple hours, days or weeks.
- the concentration of the free compound at any one time at a particular location can be controlled.
- the therapeutic effect can be displayed for longer periods of time.
- the slow -release modality can be controlled by the chemistry of the coordination bond.
- the presence of potential electron- donors in the environment of the coordination bond for instance glutathione in the intracellular environment to which the complex of the invention is targeted
- the release can be environment-induced, based on the chemistry of the coordination bind, wherein a nitrogen-platinum bond is for instance stable but reversible, and formes a preferred embodiment.
- the therapeutic compound may often be a small molecule
- the small molecule drug is attached directly via a coordination bond to the (transition) metal ion complex. This results in a reversible binding between the targeting complex and the therapeutic compound, and thus provides an inherent release function.
- the present invention provides for a targeting moiety in the form of a moiety that allows the targeting complex to be mobile (capable of moving through the body of the subject) until that point where the targeting moiety has recognized or has reached it's particular cellular target.
- the targeting moiety has the form of a selective homing moiety with specificity for a defined organ, tissue, cell, receptor or other biomolecule.
- the targeting moiety may comprise a binding pair or comprise a moiety with affinity for particular cell surface molecules such as receptors. Suitable are in this context the receptor ligands disclosed herein.
- the same accounts for in situ diagnostic compounds, i.e. compounds which are used for imaging or detection of particular cell surface molecules on organs, tissues or cell types (tumours).
- the present invention provides for a targeting moiety in the form of a moiety that allows the targeting complex to be fixed to a particular location in the body, so that the slow-release modality of the complex may be confined to a specified location, in particular the location where the complex of the invention is applied.
- the complex may for that purpose comprise a targeting moiety containing a molecule that inhibits circulation in the body, for instance a PEG molecule.
- PEG polyg.g., polyethylene glycol glycol, polyglyceride, poly(ethylene glycol)
- targeting thus refers to the tendency of the complex to accumulate or remain at a particular site of the body of a subject.
- a stable linkage between a protein and a targeting moiety may be realized by using a recombinant form of the protein that has been provided with a HIS-tag, i.e. a stretch of amino acid (histidine) residues attached to the protein molecule that is commonly used as an aid in its purification.
- HIS-tag i.e. a stretch of amino acid (histidine) residues attached to the protein molecule that is commonly used as an aid in its purification.
- the presence of both methionine residues and histidine residues in the HIS-tag make it amenable to react the metal ion linker to the HIS-tag, which may prove beneficial with respect to the therapeutic activity of the resulting complex.
- the metal ion linker may also be reacted with preference to methionine start codons of recombinant proteins that do not have a HIS-tag. This approach has wide commercial applicability because with this universal technology all recombinant protein drugs can be efficiently linked to targeting moie
- Therapeutic compounds in the form of recombinant proteins may be produced by standard recombinant techniques.
- recombinant vectors encoding for the desired protein with a HIS-tag and optionally a cleavage site may be constructed by known methods.
- a coupling method of the present invention comprises the step of allowing the (transition) metal ion complex to form coordination bonds with the targeting moiety and the deliverable compound.
- the (transition) metal ion complex may first form coordination bonds with the targeting moiety and, the resulting conjugate may subsequently be brought into contact with the deliverable compound so as to allow the formation of coordination bonds between the metal ion of the targeting moiety— metal conjugate and the deliverable compound. Also, all compounds may be brought together and the formation of the various bonds may commence simultaneously.
- bonds between the metal and deliverable compound and between the metal and the targeting moiety may be the same or different.
- the deliverable compound-metal bond may comprise a Pt-S adduct
- the targeting moiety-metal bond may comprise of a Pt-N adduct, or vice versa.
- Other types of bonds which will form coordination bonds with the metal ion may be selected by one skilled in the art.
- the reaction parameters for the bonding reaction(s) may include the choice for a specific pH value.
- the pH as used herein should be interpreted as the pH value in water at 20 0 C.
- the formation of Pt-S adducts is pH independent whereas formation of Pt-N adducts is pH dependent.
- one or more S-reactive sites are selectively labelled over one or more nitrogen containing sites by making use of the pH.
- the pH of the bonding reaction may be chosen at a pH below the lowest pKa of any of a deliverable compound or targeting moiety N-reactive sites that should not be bonded, allowing preferential bonding to S- reactive sites.
- S-reactive sites are preferentially labelled over N-reactive sites at acidic pH. Therefore, the pH may be used for preferential binding of S based ligands over N based ligands.
- the formation of a Pt-S adducts is a one step process. A reactive group leaves the metal ion complex upon S donating an electron pair to metal ion.
- metal ion-X becomes metal ion-O and eventual metal ion- N.
- the above described metal ion bonding relates in particular to Pt-ion coordination bonding.
- the presence of ions may also be used to control the selectivity of the metal ion (preferably platinum) complex for forming coordination bonds with N-reactive sites.
- one or more leaving ligands preferably anionic moieties, are used in the inhibition of the coupling of a metal ion complex to a N-reactive site, in order to enhance preferential coupling to an S- reactive site. Examples of such leaving ligands include Cl", NO3", HCO3",
- Z is defined herein as a hydrogen moiety or an alkyl or aryl group having from 1 to 10 carbon atoms. Particularly good results have been achieved by using salts comprising an anionic moiety, of which chloride and nitrate is particularly preferred.
- the counter ions are preferably alkali cations, alkali earth cations or cations also used to direct the bond formation.
- the total ionic strength of said anionic moieties used in the inhibition of bonding to a N- reactive site is at least 0.1 mol/1 . More preferably the total ionic strength is in the range of 0.1 to 0.5 mol/1.
- the presence of other (transition) metal ions in the reaction mixture may also be used for selection of the reactive site to be labelled.
- several (transition) metal ions have been found suitable to prevent or slow down bonding to an S-reactive site or to make a bonded Pt-S adduct labile, so that effectively N-reactive sites are preferentially bonded over S-reactive sites.
- it is also possible to direct the bonding reaction by making use of geometrical isomers of a metal ion complex - e.g. a cis-platinum complex and a £rcms-platinum complex, - such that the metal ion complex is specifically bonded to either a sulphur containing reactive site or to a nitrogen containing reactive site.
- This form of preferential bonding of targeting moieties or deliverable compounds may hold specific advantages when specific bonds between the various components of the complex of the invention are required and may thus be used to control the bonding of the ion metal complex to either the targeting moiety or the deliverable compound when the coupling reaction is performed in a reaction mixture comprising both the targeting moieties and deliverable compounds.
- a method according to the invention may further be fine tuned by parameters such as temperature, preferably varied in the range between 0 °C and 120 °C, more preferably in the range between 20 0 C and 70 °C; reaction time, commonly in the range between 1 min and 48 hours, preferably in the range between 10 min and 24 hours, more preferably in the range between 25 min and 15 hours; concentration of the reagents,, molar ratio of the reagents, overall net charge of the metal ion complex, and the like.
- parameters may be adjusted depending upon the particular application in any way known in the art.
- the overall net charge of the metal ion complex affects the specificity of metal ion- N adduct formation, for example, the specificity of Pt-N adduct formation in histidine at neutral pH.
- Neutral Pt-complexes form Pt-N adducts whereas positively charged platinum complexes do not.
- Positively charged Pt complexes display differential bonding towards N adducts above the isoelectric point of the peptide, protein, and the like.
- a method according to the present invention also makes it possible to differentiate between distinct N- reactive sites or distinct S-reactive sites, by choosing the correct conditions, such as described in European patent application EP 1 262 778.
- conjugates Purification, quality and stability of the conjugates may be performed and assessed using standard techniques. For instance, binding to and uptake of conjugates in target cells may be studied in- ⁇ itro using radiolabeled products or with immunohistochemical techniques. Suitable in- ⁇ itro test systems may for instance include cells and organ slices. Organ and cellular distribution of the developed complexes may for instance be studied in healthy animals and in experimental disease models (i.e. a rat or mouse models).
- the cell-targeting complexes may be combined with pharmaceutically acceptable carriers to form a pharmaceutical composition.
- the carriers may be chosen based on the route of administration as described below, the location of the target tissue, the drug being delivered, the time course of delivery of the drug, etc.
- compositions comprising a cell-targeting complex according to the present invention.
- the composition comprises a pharmaceutically acceptable carrier admixed with the cell-targeting complex of the invention.
- pharmaceutically acceptable carrier means an inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- pharmaceutically acceptable carrier is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEEN 80 ; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other nontoxic
- a method of targeting deliverable compounds to selected cell populations comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition according to the invention.
- effective amount means an amount of a drug or pharmacologically active compound that is nontoxic but sufficient to provide the desired local or systemic effect and performance at a reasonable benefit/risk ratio attending any medical treatment.
- administering and similar terms mean delivering the composition to the individual being treated such that the composition is capable of reaching the intended target site or the systemic circulation.
- the composition is preferably administered to the individual by systemic administration, typically by intravenous, subcutaneous, intraperitoneal or intramuscular administration.
- Injectables for such use can be prepared in conventional forms, either as a liquid solution or suspension or in a solid form suitable for preparation as a solution or suspension in a liquid prior to injection, or as an emulsion.
- Suitable excipients or carriers include, for example, water, saline, dextrose, glycerol, ethanol, and the like; and if desired, minor amounts of auxiliary substances such as wetting or emulsifying agents, buffers, and the like can be added.
- Other carriers can be used and are well known in the art.
- the pharmaceutical compositions of this invention can be administered to a subject by any means known in the art including oral and parenteral routes.
- subject refers to humans as well as non-humans, including, for example, mammals, birds, reptiles, amphibians and fish.
- the non-humans are mammals (e. g. , a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig).
- parenteral routes are preferred since they avoid contact with the digestive enzymes that are found in the gastrointestinal tract.
- compositions may be administered by injection (e.g. , intravenous, subcutaneous or intramuscular, intraperitoneal injection), rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).
- injection e.g. , intravenous, subcutaneous or intramuscular, intraperitoneal injection
- rectally rectally
- vaginally topically
- topically as by powders, creams, ointments, or drops
- inhalation as by sprays.
- sterile injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, U. S. P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono-or diglycerides.
- the cell-targeting complex is suspended in carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) TWEEN 80.
- carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) TWEEN 80.
- the injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the cell-targeting complex with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the cell-targeting complex.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the cell-targeting complex.
- Dosage forms for topical or transdermal administration of an inventive pharmaceutical composition include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches.
- the cell- targeting complex is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required
- Ophthalmic formulations, ear drops and eye drops are also contemplated as being within the scope of this invention.
- the ointments, pastes, creams and gels may contain, in addition to the cell-targeting complex of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
- Such dosage forms can be made by dissolving or dispensing the cell- targeting complex in a proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin.
- the rate can be controlled by either providing a rate controlling membrane or by dispersing the cell- targeting complex in a polymer matrix or gel.
- Powders and sprays can contain, in addition to the cell-targeting complex of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these drugs.
- Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons .
- the cell-targeting complex When administered orally, the cell-targeting complex are preferably, but not necessarily, encapsulated.
- suitable encapsulation systems are known in the art ("Microcapsules and Nanoparticles in Medicine and
- the cell-targeting complex may be encapsulated within biodegradable polymeric microspheres or liposomes.
- biodegradable polymeric microspheres or liposomes examples include carbohydrates such as alginate, cellulose, polyhydroxyalkanoates, polyamides, polyphosphazenes, polypropylfumarates, polyethers, polyacetals, polycyanoacrylates, biodegradable polyurethanes, polycarbonates, polyanhydrides, polyhydroxyacids, poly (ortho esters) and other biodegradable polyesters.
- lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine,sphingolipids, cerebrosides and gangliosides.
- phosphatidyl compounds such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine,sphingolipids, cerebrosides and gangliosides.
- compositions for oral administration can be liquid or solid.
- Liquid dosage forms suitable for oral administration of inventive compositions include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.
- the oral compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
- adjuvant refers to any compound which is a nonspecific modulator of the immune response.
- the adjuvant stimulates the immune response. Any adjuvant may be used in accordance with the present invention.
- a large number of adjuvant compounds is known in the art (Allison, Dev. Biol. Stand. 92: 3,1998 ; Unkeless et al.,Annu. Rev. Immunol. 6: 251,1998 ; and Phillips et al., Vaccine 10: 151,1992).
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the encapsulated or unencapsulated cell-targeting complex is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or calcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetylene glyco
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
- the exact dosage of the cell-targeting complex is chosen by the individual physician in view of the subject to be treated. In general, dosage and administration are adjusted to provide an effective amount of the cell-targeting complex to the subject being treated.
- the "effective amount" of an cell-targeting complex refers to the amount necessary to elicit the desired biological response.
- the effective amount of cell- targeting complex may vary depending on such factors as the desired biological endpoint, the drug to be delivered, the target tissue, the route of administration, etc.
- the effective amount of cell-targeting complex containing an anti-cancer drug might be the amount that results in a reduction in tumor size by a desired amount over a desired period of time.
- compositions of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
- dosage unit form refers to a physically discrete unit of cell-targeting complex appropriate for the subject to be treated. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs.
- animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- Therapeutic efficacy and toxicity of cell-targeting complex can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g. , ED 50 (the dose is therapeutically effective in 50% of the population) and LD50 (the dose is lethal to 50% of the population).
- the dose ratio of toxic to therapeutic effects is the therapeutic index and it can be expressed as the ratio, LD 50/ED 50.
- Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used in formulating a range of dosage for human use.
- the cell-targeting complexes of the present invention may for instance target cells that play a major role in liver fibrosis (activated hepatic stellate cells), in renal fibrosis (kidney proximal tubular cells), in chronic inflammatory disorders (activated endothelial cells) or tumour angiogenesis (angiogenic endothelial cells).
- the drugs incorporated in the complexes may for instance intervene in inflammatory or fibrotic processes (pentoxyfillin, kinase inhibitors, angiotensin II receptor blockers, pyrrolidine dithiocarbamate), or programmed cell death (TNF related apoptosis inducing ligand).
- TNF programmed cell death
- Pentoxifylline 3,7-dimethyl-l-(5-oxohexyl)purine-2,6-
- TNF-alpha synthesis inhibitor (TNF-alpha synthesis inhibitor; antidione inflammatory agent) Losartan 2-butyl-5-chloro-3-((4-(2-(2H-tetrazol-5- (angiotensin II receptor antagonist) yl)phenyl)phenyl)methyl)imidazol-4- yl] methanol
- NFjB transcription factor nuclear factor kappa-B
- Pt(en)C12 platinum(ethylenediamine) dichloride
- DMF dimethylformamide
- Pt(en)C12 platinum(ethylenediamine) dichloride
- cisULS mononitrate platinum(ethylenediamine) dichloride
- AgNO3 38.5 mg, 0.227 mmol, dissolved in 1 ml of DMF
- Various drug molecules were reacted with the resulting cisULS mononitrate at the indicated conditions and molar ratios.
- reactions were conducted at a 1:1 molar until formation of the desired product was complete, as analyzed by HPLC.
- reaction conditions for the drug-ULS-carrier complexation are a 10:1 ratio of drug-ULS: carrier, a buffer of pH 8, a temperature of 37 0 C and a reaction duration of 24h. However, reaction conditions may vary depending on the composition of the product.
- Pentoxifylline (PTX, 43.2 mg, 0.155 mmol, dissolved in 1 ml of DMF) was reacted with cisULS (0.25 mmol) at 60°C for 2 days. DMF was removed by rotary evaporation, after which the residue was dissolved in 2 ml of water and again taken to dryness under reduced pressure. The crude product was dissolved in water (2 ml) and stored overnight at -20°C, after which unreacted Pt(en)C12 precipitated as yellow crystals, which were removed by centrifugation (10 minutes at 14000 rpm). The identity and purity of the final product PTX-cisULS was checked by HPLC (95%), NMR and mass spectroscopy. PTX-cisULS was stored at 4 0 C until further use. Yield: 105 mg (0,166 mmol, 107% yield).
- PTX-cisULS 1 H NMR (D 2 Q): ⁇ H 1.62 (m, 4H, CH 2 (CH 2 )SCH 2 ), 2.25 (s, 3H, CHsCO), 2.58 (m, 6H, COCH 2 , H2N(CH 2 )2NH 2 ), 3.99 (t, J 6.56 Hz, 2H, CH 2 N), 4.02 (s, 3H, CONCH 3 ), 4.55 (s, 3H, CNCH 3 C), 5.59 (m, 4H, H 2 N(CH 2 )SNH 2 ), 8.48 (s, IH, CH) ppm.
- PTX-cisULS ionsprav MS calculated mass: 568. detected: 568 [M]; 550 [M- Cl+OH] . Both PTX-ULS species will react equally to the carrier in the second reaction step.
- the anti-inflammatory compound PTX will be conjugated to the carrier protein mannose-6-phosphate modified human serum albumin (M6PHSA).
- M6PHSA binds to the insulin-like growth factor II/mannose-6-phosphate receptor, which is highly expressed during liver fibrosis on activated hepatic stellate cells (HSC)[I].
- HSC activated hepatic stellate cells
- M6PHSA was synthesised as described previously [2] and stored after lyophilisation at -2O 0 C until further use.
- 10 mg of M6PHSA (14.3 nmol) was dissolved in 1 ml of 20 niM tricine/NaNO3 buffer pH 8.3.
- PTX-cisULS (143 nmol) was added and the pH was checked and corrected if necessary. The mixture was reacted overnight at 37°C, after which unreacted PTX-cisULS was removed by size-exclusion chromatography using disposable PDlO columns (Amersham Biosciences), or by dialysis against PBS at 4°C. The final product was sterilised by filtration via a 0.2 ⁇ m filter and stored at -20 0 C.
- PTX-cisULS-M6PHSA was characterised for protein content (BCA method) and for drug content by HPLC analysis. Typically, the coupled drug was released from M6PHSA by overnight incubation with 0.5M KSCN in PBS at 80 0 C.
- the released PTX was determined using a standard HPLC system equipped with a UV detector operated at 274 nm and a thermostated column oven operated at 4O 0 C. Elutions were performed on a ⁇ Bondapak Guard-pak C18 precolumn in combination with a 5 ⁇ m Hypersil BDS C8 column (250x4.6 mm, Thermoquest Runcorn, UK) using a mobile phase consisting of acetonitrile/water/trifluoracetic acid (25/75/0.1) at 1 ml/min. PTX eluted at 6 min after injection. Typically, the product contained 5-8 coupled drug molecules per M6PHSA when a 10-fold molar excess was used in the reaction.
- Losartan potassium (2-butyl-4-chloro-l-[p-(o-lH-tetrazol-5-yl- phenyl)benzyl]imidazole-5-methanol monopotassium) is an angiotensin II receptor (type ATi) antagonist.
- Losartan (32 ⁇ mol, 10 mg/ml of the potassium salt of losartan in DMF) was reacted with cisULS (32 ⁇ mol) at 60 0 C for 3 days. Consumption of the starting material was monitored by analytical HPLC. Mass spectrometry analysis confirmed the presence of the 1:1 losartan-cisULS species after completion of the reaction.
- the angiotensin II receptor antagonist losartan will be conjugated to the carrier protein M6PHSA.
- M6PHSA binds to activated hepatic stellate cells (HSC) within the fibrotic liver.
- HSC hepatic stellate cells
- the coupled drug losartan interferes in the renin-angiotensin system.
- 10 mg of M6PHSA (14.3 nmol) was dissolved in 1 ml of 20 mM tricine/NaNO3 buffer pH 8.3.
- Losartan-cisULS (143 nmol) was added in a 10-fold molar excess and the pH was checked and corrected if necessary.
- Losartan-cisULS-M6PHSA contained approximately 7 coupled losartan molecules per mole of protein, as was calculated form its protein content and drug content (HPLC). HPLC analysis of losartan was carried out using a Novapak C18 column and a mobile phase consisting of acetonitrile/water/trifluoroacetic acid at a 23/77/0.1 ratio. Eluted compounds were monitored at 225 nm. Synthesis of losartan-cisULS-Lvsozyme
- the angiotensin II antagonist losartan will be conjugated to the carrier protein lysozyme (LZM). Since LZM and other low molecular weight proteins undergo glomerular filtration and subsequential uptake in proximal tubular cells, the resulting product losartan-cisULS-LZM will be accumulated in the kidney after in vivo administration. As such, the developed conjugate can serve in the delivery of the angiotensin antagonist to the kidney. One additional methionine group was introduced into LZM prior to the reacting with the drug-cisULS molecule.
- LZM carrier protein lysozyme
- Boc-L-methionine hydroxysuccinimide ester (17 ⁇ mol; 10 mg/ml in DMSO) was added to lysozyme (14 ⁇ mol; 10 mg/ml in 0.1 M sodium bicarbonate buffer pH 8.5) and stirred for 1 h at room temperature.
- the product was dialysed against water and lyophilised.
- the methionine-modified lysozyme contained one to two extra methionine groups as was confirmed by electron- spray mass analysis.
- the product was stored at -20°C until further use.
- Losartan-cisULS (0.72 ⁇ mol; 3 mg/ml in DMF) was added to a solution of methionine modified LZM (0.36 ⁇ mol; 10 mg/ml in 20 mM tricine/sodium nitrate buffer pH 8.5) and the mixture was incubated at 37°C for 24 h.
- the resulting product was purified by dialysis against water for 2 days, filtered through 0.2- ⁇ m membrane filter, lyophilised and stored at ⁇ 20°C.
- the coupling of losartan with lysozyme in a 1:1 molar ratio was confirmed by mass analysis of the final product and HPLC analysis of the coupled drug after its release from the carrier.
- a Platelet derived growth factor (PDGF) receptor Tyrosine Kinase Inhibitor will be conjugated to the carrier protein M6PHSA. As described above, this carrier binds to activated hepatic stellate cells (HSC) within the fibrotic liver. The coupled drug PTKI interferes in the PDGF kinase pathway.
- PDGF BB is one of the most potent mitogens for HSC proliferation and plays an important role in fibrotic processes.
- PTKI-cisULS PTKI (4-Chloro-N- [4-methyl-3-(4-pyridin-3-yl-py ⁇ imidin-2-ylamino)- phenyl]-benzamide, (7.2 ⁇ mol, 10 mg/ml in DMF) was mixed with an equimolar amount of cisULS (7.2 ⁇ mol, 20 mM in water). The reaction mixture was heated at 37°C for 24h after which consumption of the starting material was monitored by analytical HPLC. An additional amount of cis-ULS was added (0.5 equivalent, 3.6 ⁇ mol) and the reaction was continued for 48h at 37°C. The reaction mixture was concentrated under reduced pressure and redissolved in methanol (600 ⁇ l).
- PTKI-ULS was conjugated to M6PHSA according to a similar protocol as has been described above for other drug-ULS-M6PHSA conjugates.
- PTKI- ULS-M6PHSA and M6PHSA were analyzed by size-exclusion chromatography and anion exchange chromatography to verify that coupling of PTKI-ULS did not alter the properties of the M6PHSA protein.
- the amount of PTKI coupled to M6PHSA was analyzed by isocratic HPLC after competitive displacement of the drug by overnight incubation at 80 0 C with excess of the platinum ligand potassium thiocyanate (KSCN, 0.5M in PBS).
- KSCN platinum ligand potassium thiocyanate
- Elutions were performed on a Waters system (Waters, Milford, MA, USA) equipped with a 5 ⁇ m Hypersil BDS C8 column (250x4.6 mm, Thermoquest Runcorn, UK), a thermostated column oven operated at 40 0 C and an UV detector operated at 269 nm.
- the mobile phase consisted of acetonitrile/water/trifluoracetic acid (40/60/0.1, pH 2) at a flow rate of 1.0 ml/min with a sensitivity of 0.01. Retention times: PTKI: 7 min; PTKI-ULS: 5 min.
- SB202190-cisULS SB202190 (4-(-Fluorophenyl)-2-(4-hydroxy-phenyl)-5-(4-pyridyl)-lH- imidazole, 5.43 ⁇ mol) was dissolved in DMF at a concentration of 10 mg/ml, and reacted with cisULS 5.43 ⁇ mol, 20.5 niM in DMF) at 50 0 C for 2 h. The reaction was followed by HPLC. After the reaction was completed, the mixture was evaporated to dryness under reduced pressure, affording a pale yellow solid that was analysed by HPLC, 1 HNMR and electronspray mass spectrometry.
- Mass Spectrometry analysis confirmed the presence of the target 1:1 drug:ULS species and 1 H NMR studies indicated that binding of SB202190 to cis-ULS takes place via co-ordination of the N- donor of the pyridine ring contained in the drug to the Pt(II) metal. Yield was 92%.
- the p38 Mitogen Activated Pathway (MAP) kinase inhibitor SB202190 will be conjugated to the carrier protein human serum albumin (HSA).
- HSA human serum albumin
- the resulting product will be equipped with RGD- peptide homing ligands that bind to ⁇ v ⁇ 3 integrin, a receptor that is expressed by endothelial cells in newly formed blood vessels [3].
- the HSA core protein will be equipped with polyethylene glycol (PEG) groups, which infer stealth properties in the final construct. As such, these PEG ligands can prevent the uptake by non-target cells.
- PEG polyethylene glycol
- SB202190-cisULS conjugation of SB202190-cisULS to the protein was verified by taking UV- spectra, since the final product displayed a specific absorption at 334nm which was due to the conjugated drug and not present in the parent HSA.
- the coupled drug was released from HSA by overnight incubation with 0.5M KSCN in PBS at 80°C.
- the released SB202190 was determined using a standard HPLC system equipped with a C18 ⁇ Bondapak column and a UV detector operated at 254 nm. Compounds were eluted with a mixture of water/acetonitrile/ trifluoroacetic acid 80/20/0.1 at 1 ml/min.
- the product contained 5-8 coupled drug molecules per HSA when a 10-fold molar excess of SB202190-cisULS was used in the reaction.
- SB202190-cisULS-HSA was modified with PEG and RGD-peptide groups.
- SB202190-cisULS-HSA dissolved in PBS was treated with a 50-fold molar excess of VNS-PEG-NHS (Nektar, Alabama, USA; 20 mg/ml in water), which was added dropwise. The mixture was protected from light with tin foil and incubated for Ih at room temperature on a rollerbank.
- the cyclic RGD peptide c(RGDfK-Ata) (Ansynth Service, Roosendaal, The Netherlands) was dissolved at 10 mg/ml in a 1:4 acetonitrile/water mixture.
- the RGDpeptide was added dropwise to the reaction mixture at a mole: mole ratio of 55:1, after which hydroxylamine was added in a final concentration of 50 mM.
- the reaction was carried out overnight at room temperature while protected from light.
- SB202190 will be conjugated to the carrier protein lysozyme (LZM).
- LZM carrier protein lysozyme
- the developed SB202190-cisULS-LZM conjugate can serve in the delivery of the p38 MAPkinase inhibitor to the kidney.
- Methionine-modified lysozyme (met-LZM, see above; 2.6 ⁇ mol; 10 mg/ml in tricine/sodium nitrate buffer pH 8.5) was treated with SB202190-ULS (7.8 ⁇ mol; 10 mg/ml in DMF), after which the mixture was incubated at 37°C for 24 h.
- the product was dialysed against water, filtered through 0.2- ⁇ m membrane filter, lyophilised and stored at -2O 0 C.
- the coupling of SB202190 with lysozyme in a 1:1 ratio was confirmed by electron-spray mass analysis of the final product.
- coupling of the drug was confirmed by HPLC analysis of the coupled SB202190 after release of the drug from the SB202190-lysozyme conjugate.
- the conjugate was incubated with 0.5M potassium thiocyanate (KSCN) dissolved in 0.1 M phosphate buffer saline at 80 0 C for 24 h to release SB202190 completely.
- SB202190 was estimated using HPLC (Waters, Milford, MA, USA) analysis method described elsewhere.
- the samples were added with an internal standard, SB202190 derivative, and extracted with 2 ml of diethylether three times.
- the extract was dried at 50 0 C and the residue was reconstituted in 100 ⁇ l of mobile phase (acetonitrile:water:trifluoroacetic acid, 30:70:0.1 v/v/v). Twenty-five microliter of it was injected into HPLC column (Thermo-Hypersil Keystone, Bellefonte, PA) and detected at 350 nm.
- the peak height ratios of SB202190 and internal standard were used to calculate the concentration.
- the degree of SB202190 substitution in the conjugate was found to be 1 mole of SB202190 per mole of lysozyme. No free SB202190 was found in the final preparation.
- Dendrimers are branched polymers that can be equipped with drugs and homing devices in an analogous manner as described above for albumin-based drug delivery systems.
- the present examples describe the development of drug-dendrimer conjugates prepared with PAMAM dendrimers.
- the developed products can be applied for drug delivery to various targets, depending on the molecular size and further derivatizion with homing devices or other functional groups like PEG. This latter class of products is exemplified by the RGD_PEG equipped drug-dendrimer complex.
- PAMAM-NH2 dendrimer (generation 3) was equipped with methionine groups by reacting Boc-L-methionine hydroxysuccinimide ester (14.4 ⁇ mol; 10 mg/ml in acetonitrile) with the dendrimer (1.4 ⁇ mol, 10 mg/ml in PBS) for Ih at room temperature. The product was purified by dialysis, against water and lyophilized.
- PAMAM-NH2 dendrimer (generation 4) was equipped with methionine groups (synthesis ratio 35:1) following the same protocol, and with p-isothiocyanate-benzyl-DTPA groups (synthesis ratio 3:1) to facilitate labeling of the complexes with a radioactive tracer isotope. The resulting carrier was purified by dialysis against PBS.
- G3-Dendrimers were reacted with SB202190-cisULS (synthesis ratio 4:1) while G4-dendrimers were reacted at a 40:1 ratio, according to the protocol described above for other drug-carrier complexes, the final products were purified by dialysis and contained an average of 1:1 (G 3D) or 20:1 (G4D) drug/dendrimer, as determined by UV absorbance at 360 nm (absorbance of conjugated SB201190-ULS).
- PAMAM-NH2 dendrimer generation 4 was equipped with VNS-PEG- NHS (synthesis ratio 40:1) and RGD-peptide (ratio 50:1) according to a similar protocol as described below for RGD-PEG equipped albumin carriers. Modification of the RGD-PEG-PAMAM dendrimer with 40:1 molar equivalents of SB202190-cisULS was carried out as described above for the PAMAM generation 4 dendrimer, and yielded a complex with an average of 15:1 drug/dendrimer, as determined by UV absorbance of the conjugated drug. l.l.e. Synthesis of PTK787-containing complexes
- VEGF vascular endothelial cell growth factor
- PTK787 which is a potent inhibitor of angiogenesis
- PTK787 (5.8 ⁇ mol, 10mg/ml in DMF) was mixed with cisULS (5.8 ⁇ mol). The resulting solution was heated at 37 0 C for 24 hours during which consumption of the drug starting material was monitored by analytical HPLC. The solvents were removed under reduced pressure and taken-up 50:50 DMF:water. Mass Spectrometry analysis confirmed the presence of the target 1:1 drug:ULS species and 195 Pt NMR and 1 H NMR studies indicated that binding of PTK787 to cisULS takes place via co-ordination of the N- donor of the pyridine ring.
- the peptide (11.1 ⁇ mol) was added drop wise to the reaction mixture at a peptide to protein molar ratio of 25:1, after which hydroxylamine was added to a final concentration of 50 mM. Hydroxylamine will release the acetyl group of the RGD peptide to obtain a free sulfhydryl group.
- the reaction was carried out overnight at room temperature while protected from light after which the product was extensively dialyzed against PBS.
- the final product RGD-HSA was stored at -20°C.
- a control conjugate RAD-HSA was prepared according to the same protocol with the control peptide c(RADf(£-S-acetylthioacetyl)K).
- RGD-HSA-PEG Synthesis of RGD-HSA-PEG.
- RGD-HSA 13mg, 193nmol
- PBS PBS
- mPEG-SMB mPEG succinimidyl ⁇ -methylbutanoate
- SEC size exclusion chromatography
- HSA (lOmg, 148nmol) was dissolved in PBS and incubated with a 50- fold molar excess of vinylsulfone-polyethylene glycol-N-hydroxysuccininiide ester (VNS-PEG-NHS; Nektar, Alabama, USA; 20 mg/ml in water, 7.4 ⁇ mol).
- VNS-PEG-NHS vinylsulfone-polyethylene glycol-N-hydroxysuccininiide ester
- the mixture was protected from light with aluminum foil and incubated for Ih at room temperature while gently shaking on a spiramix roller bank.
- RGD peptide (8.14 ⁇ mol) was added in a 55-fold molar excess over HSA followed by hydroxylamine addition as described above. Reaction was carried out over night at room temperature while protected from light.
- Remaining VNS groups were quenched by addition of cysteine (8.14 ⁇ mol; 55x molar excess over the amount of HSA), after which the product was purified by SEC as described above.
- the final products RGDPEG-HSA and RADPEG-HSA were stored at - 20 0 C.
- the ALK-5 inhibitor TGF-beta Kinase Inhibitor, TKI
- TKI 3-(Pyridin-2-yl)-4-(4-quinonyl)-lH-pyrazole (CalBiochem)
- LZM kidney-directed carrier protein LZM
- TKI inhibits signalling cascades that are activated by TGF-beta, one of the most important profibrotic growth factors. It is also a potent inhibitor of p38 MAPkinase.
- TKI-cisULS TKI (9.98 mg, 37 ⁇ mol) was dissolved in DMF at a concentration of 10 mg/ml after which an equimolar amount of a freshly prepared solution of cisULS was added. The mixture was heated at 37 0 C overnight. The product was analyzed by HPLC, LC-MS and Pt-NMR These analyses confirmed a 1:1 coupling ratio of TKI and ULS. Yield: 77.3 % (by HPLC).
- TKI-cisULS was reacted with met-LZM as described above for conjugation of other drug-ULS-carrier complexes.
- the product was purified by dialysis against water and lyophilized and stored at -20°C. Ion-spray MS analysis confirmed the formation of TKI-LZM conjugate. The amount of conjugated drug was quantified after releasing it from the linker. On average,
- the ROCK inhibitor Y27632 will be conjugated to the kidney-directed carrier protein LZM.
- Y27632 (38 ⁇ mol, 10 mg/ml in water) was basidified with IM NaOH to pH 8.5 and reacted with cisULS (66 ⁇ mol) at 50 °C overnight. Consumption of the starting drug and formation of the products was followed by HPLC and LC-MS. The excess of ULS is then precipitated by the addition an equivalent volume of a 1:1 DMF:water solution with a 20 mM concentration in NaCl and a subsequent overnight stirring at ambient temperature. Yellow solids then are removed by filtration. Yield: 50 % (HPLC; for the crude product). Synthesis of Y27632-cisULS-Lvsozvme
- Y27632-cisULS was reacted with met-LZM as described above for conjugation of other drug-ULS-carrier complexes.
- the product was purified by dialysis against water and lyophilized and stored at -20°C. Ion-spray MS analysis confirmed the formation of the conjugate. The amount of conjugated drug was quantified after releasing it from the linker. On average, 1-2 Y27632 molecules were conjugated per LZM.
- the reaction mixture was reacted overnight at room temperature.
- the formation of cis-[PtCl(NH3) 2 (Bocl,n)] + was checked by 195 Pt NMR, directly from the reaction solution. A single signal was observed at -2399 ppm, which was assigned to a C1N3 environment around the platinum.
- Cis- [Pt(ONO 2 )(NH 3 ) 2 (Bocl,n)] + was treated with 0.8 equiv. of PTX (0.074 g, 0.266 mmol) at 75 0 C, overnight in the dark. After overnight the formation of the desired species were checked by 195 Pt NMR. A signal was observed at - 2487, -2484 and -2492 ppm for complexes RBol,3, RBocl,4 and RBocl,5, respectively. These values are in agreement with a 4N environment around the platinum centre.
- these complexes can be linked to a targeting device, such as but not limited to modified albumin, antibody, ... .
- PTK787-transULS PTK787 (5.77 ⁇ mol) was dissolved in DMF at a concentration of 10 mg/niL. An equimolar of trans-ULS (18.7 mM in DMF) was added and the resulting mixture was heated for 37 0 C for 2 hours. An additional 0.25 molar equivalent of transULS then was added and the resulting solution was heated at 37 0 C for 1.5 hour. Any excess of ULS may be removed by NaCl treatment as described in the synthesis of Y27632-cisULS. The solvents may be removed under reduced pressure._The reaction was followed by HPLC. Mass
- Spectrometry analysis confirmed the presence of the target 1:1 drug:ULS species.
- SB202190-transULS The species was formed by reacting SB202190 (5.43 ⁇ mol) in DMF (10 mg/mL) with an equimolar of transULS in DMF (18.7 mM), for 1 hour at 37 0 C .
- Potassium iodide (2g, 12 mmol) was added to a solution of 1 g (2 mmol) of KgPtCU in 50 ml of water.
- the resulting dark solution of KzPtI 4 was treated with 0.16 ml (2.4 mmol) of ethylenediamine and allowed to stand at room temperature for several hours. Then, the dark yellow precipitate of Ptenl2 was collected by filtration, washed with water, ice-cold ethanol and ether, and dried in air. Yield: 1 g (99%).
- Silver nitrate (0.66 g, 3.9 mmol) in 5 ml of water was then added to the suspension of Ptenl2 (1 g, 2 mmol) in 25 ml of water upon stirring.
- Methanesulfonyl chloride (0.88 ml, 11.4 mmol) was gently added to a stirred solution of 1.95 g (9.5 mmol) of 2a and 2 ml (14.3 mmol) of triethylamine in 50 ml of dichloromethane at 0 0 C. The resulting solution was stirred for 1 h at 0 0 C and for 30 min at room temperature. Then the solution was successively washed with 1 M HCl (50 ml), water (50 ml), 10% aqueous solution of Na2CO3 (50 ml) and brine (50 ml). The organic phase was dried (Na 2 SO 4 ), filtered and evaporated to get the product.
- TRAIL tumor necrosis factor [TNF]-related apoptosis-inducing ligand
- Human hisTRAIL was diluted to a concentration of 0.7mg/ml in PBS containing 10% glycerol.
- SMCC-ULS was dissolved at a concentration of 10mg/ml in 2OmM NaCl; all samples were adjusted to pH 7.4.
- His-TRAIL 500ug, 7,6nmol was incubated with SMCC-ULS (76 nmol) for 4 hours at
- biotin-ULS -TRAIL which can be complexed with RGD -equipped carriers via avidin-biotin interaction, as examplified by RGD-PEG-avidin.
- the resulting bio-ULS- TRAIL//RGD-PEG-avidin complexes can interact with angiogenic endothelium and by this redirect TRAIL to tumor cells and tumor blood vessels.
- Bio-ULS-TRAIL was prepared in a similar protocol as described above, using biotin-ULS at a 10:1 molar ratio over the amount of hisTRAIL.
- the final product was purified by dialysis against PBS/10% glycerol and stored at -20 0 C. Incorporation of biotin was conformed by SDS-PAGE and anti-biotin Western blotting using streptavidin-peroxidase.
- RGD-PEG-avidin was prepared in an analoguous protocol as described for RGD-PEG-HSA, using 2mg avidin (30 ⁇ mol), a 10-fold molar excess of heterobifunctional vinylsulfone-polyethylene glycol-N-hydroxysuccinimide ester (lmg, 300 nmol) and an 11-fold molar excess of RGD-peptide. An average of 5.4 RGD groups was incorporated per avidin.
- the stability of the drug-carrier linkage was investigated by incubating cell targeting complexes at 37°C under several conditions, e.g. buffers, buffers spiked with drug releasing substances or biological media. Typically, released drug was analyzed by HPLC and expressed as percentage of the total amount of conjugated drug/targeting complex.
- Typical examples of drug release profiles are depicted in Figure 4.
- Panel A Drug release profile of PTX-cisULS-M6PHSA upon incubation at 37°C in serum/PBS 1:1.
- PTX-cisULS-M6PHSA only slowly released drug in serum indicating that the linkage between drug and carrier displays adequate stability which will enable the conjugate to reach target cells.
- the observed release profile would allow for a slow release profile of the drug from a drug carrier that is not actively binding to specific target cells.
- Such a product could liberate the drug continuously, thereby controlling drug levels within the body. Examples of such preparation are for instance a subcutaneously injected depot preparation or a carrier that circulates in the blood stream.
- Panel B Release of PTX from PTX-cisULS-M6PHSA after 24h incubation at 37°C in buffer, HSC culture medium, or PBS with indicated compounds.
- the parent drug PTX can, in principle, be generated from the conjugate inside target cells.
- SB202190-cisULS-LZM upon incubation at 37°C in PBS pH 7.4, rat serum, or kidney homogenate in PBS 1/3 (w/v).
- SB202190-cisULS-LZM displayed high stability in buffer or serum, but continuously released free drug upon incubation in kidney homogenate.
- Figure_5. Effects of PTX-cisULS-M6PHSA on fibrosis markers collagen I and ⁇ -smooth muscle actin.
- HSC were incubated with PTX-cisULS-HSA, PTX- cisULS-M6PHSA (both at 1 mg/ml, equivalent to 100 ⁇ M PTX,) or 1 mM non- targeted PTX.
- Cells were stained for collagen type I or ⁇ -smooth muscle actin and counterstained with hematoxillin.
- liver fibrosis One of the hallmarks of liver fibrosis is the induced expression and production of a-smooth muscle actin (aSMA) and collagen type 1 by activated HSC. These proteins were therefore selected as read-out parameters of the antifibrotic effects of the targeted PTX. As can be seen in
- activated HSC express collagen type I in a granular staining pattern in the cytoplasm, probably corresponding to the presence of procollagen type I, while aSMA stained in a fiber-like pattern (panel A,B).
- Treatment with PTX in a concentration of 1 mM reduced the intensity of both collagen type I production and aSMA (panel G,H).
- Figure_6 Effects of PTKI-cisULS-M6PHSA on culture activated HSC (panel A) or liver slices from fibrotic rat livers (bileduct ligated rats, 3 weeks after ligation; panel B). Concentrations denote the amount of PTKI (10 ⁇ M) or the corresponding amount of M6PHSA carrier (0.1mg/nil). Gene expression levels were normalized to the expression of GAPDH and subsequently normalized to the relative expression of control cells or slices. The activity of PTKI and the cell targeting complex made thereof was studied by determination of gene-expression levels of fibrotic markers, which were analyzed by real-time quantitative RT-PCR. As can be appreciated from this example, PTKI-cisULS-M6PHSA exerted an antifibrotic effect similar to free drug PTKI, while carrier M6PHSA did not affect the investigated genes.
- Panel A Gene expression levels of IL8 in HUVEC treated with TNF and the described compounds.
- the IL8 and E-selectin genes are upregulated in HUVEC as response to treatment with TNF.
- This response can be inhibited with SB202190 at concentration of 10 ⁇ M to a level of 40%.
- Treatment with SB202190-cisULS-RGDPEG-HSA results in inhibition of this gene although to a lesser extent.
- Treatment with RGD-PEG-HSA carrier without drug did not reduce IL8 gene expression.
- inhibition of IL-8 gene expression also corresponded to a reduced production and secretion of IL8 in the culture medium (Fig 7 panel B).
- the p38 MAPkinase inhibitor SB202190 can be generated from the cell targeting complex once the compound is processed by the cells.
- the observed difference in potency of the drug can be explained by the cellular routing of the conjugate, i.e. the drug targeting construct has to be internalized and processed in the lysosomal compartments of the cell to release the active drug. These processes take longer than the simple passive diffusion of the free compound. Combined with the different behaviour of the carrier in vivo however, the RGD-targeted drug may demonstrate a superior activity versus the free compound.
- SB202190 p ⁇ 0.01 compared to respective control conjugates and to TNF ⁇ treated control.
- Figure_8 Effects of SB-cisULS-LZM (panel A) and TKI-cisULS-LZM (panel B) on the gene expressions of procollagen-Ial induced by TGF- ⁇ l in HK- 2 renal tubular cells. Cells were grown to the 80% confluency and then deprived from serum for 24 h.
- SB-cisULS-LZM conjugate (155 ⁇ g/ml), TKI- cisULS-LZM conjugate (8 or 80 ⁇ g/ml) or methionine-modified LZM (equivalent concentrations) were incubated at the time of serum deprivation whereas free SB202190 (10 ⁇ M) or TKI were added 1 h before adding TGF- ⁇ l (10 ng/ml) to the cells. The cells were further cultured for 24 h, after which RNA was isolated from the cells and mRNA expressions were determined by quantitative RT-PCR. Data represent the mean ⁇ SEM for at least 3 experiments. Differences versus control is presented as fffp ⁇ 0.001. Other differences are **p ⁇ 0.01 and ***p ⁇ 0.001.
- Drug targeting conjugates were tested for their ability to inhibit VEGF induced gene expression.
- Cells were cultured in low-serum medium (1.5% FCS) and incubated with the indicated compounds. 5 ng VEGF was added to the wells after 24h of incubation, and cell lysates were harvested after an additional 50 min.
- NE4A1 a nuclear receptor, was readily upregulated after addition of VEGF. All three drug targeting conjugates (approx. 4 ug/ml, equivalent to 500 nM of conjugated PTK787) were able to inhibit this upregulation significantly, while carrier without drug did not affect VEGF induced gene expression. Free drug was added at a concentration of 100 nM
- FIG. 1 Panel A-D: Incubation of HSC with PTX-cisULS-M6PHSA.
- A cell viability of HSC; B: caspase 3/7 activity; C: TUNEL staining; D: quantification of TUNEL positive nuclei (TUNEL/DAPI ratio), * p ⁇ 0.05 vs control.
- Panel E, F Cell viability of culture-activated HSC after incubation with losartan-cisULS-M6PHSA, and PTKI-cisULS-M6PHSA, respectively. Indicated concentrations reflect the platinum content of the conjugate, or equivalent amounts cisplatin, drug or M6PHSA.
- Figure_ll Comparison of cellular toxicity of cell targeting complexes and cisplatin on renal tubular cells (NRK-52E). Since nephrotoxicity is one of the major side effects associated with cisplatin treatment, we carefully examined the safety of the cell targeting complexes directed to the kidney. For this purpose, we incubated drug-cisULS products and drug-cisULS-LZM conjugates with kidney proximal tubular cells and assayed the cell-viability after 24h. Cells were incubated for 24h with indicated compounds, after which cell viability was determined by the Alamar blue assay. Concentrations tested corresponded to 10 and 100 ⁇ M platinum, or were equivalent to the amount of drug (SB202190) or protein (LZM).
- RGDPEG-SB-HSA and ULS containing conjugates displayed no toxicity for endothelial cells.
- Figure_13 shows that HUVEC cell viability is not affected by either non- modified hisTRAIL and biotinylated TRAIL (panel A) or RGD-equipped TRAIL (panel B). Incubations were performed for 48h at a concentration of 100 ng/nil of the recombinant protein. In another example (see below) we will demonstrate that tumour cells are responsive to TRAIL and its derivatives. We therefore concluded that HUVEC are not sensitive to TRAIL, and that the absence of cytotoxicity in transition-metal based cell targeting complexes indicated the safety of the linker system.
- TRAIL TNF-Related apoptosis Inducing Ligand
- modified TRAIL was prepared using the commercially available bio-EZ reagent (BIO -NHS-TRAIL), using KRE-Bio-ULS (BIO-ULS- TRAIL); using iodoacetic acid NHS reagent (RGD SIA-TRAIL); using VNS- PEG-NHS 3.4 kDa linker (RGD PEG-TRAIL); using SMCC-ULS (RGDULS- TRAIL).
- FIG. 14 The pharmacological activity of TRAIL and its cell targeting complexes was evaluated in Jurkat leukemic T-cells, by analyzing cell viability (48h incubation) or induction of caspases assay (4h incubation). Both types of experiments demonstrated that TRAIL and derivatives made of TRAIL were capable of killing tumour cells. Furthermore, derivatives prepared with ULS- based linkers displayed superior cytotoxic activity as compared to other chemical approaches for preparation of cell targeting complexes (panel A,B: superior activity of Bio-ULS-TRAIL over BIO-NHS-TRAIL; panel C 5 D: superior activity of RGD -ULS -TRAIL over RGD-PEG-TRAIL).
- In vitro targeting studies The interaction of cell targeting complexes with target cells was investigated in cultured target cells. Typically, in vitro targeting studies were performed by incubating target cells with the complexes, at either 4°C or 37°C. Binding and/or internalization of the complexes by target cells was detected by either immunohistochemical staining for the complex (e.g. anti-HSA or anti- LZM staining) or by quantification of a radioactive reporter group that had been introduced in the complex (e.g. 125 I). Representative examples of targeting studies are depicted in Figures 15-17.
- Figure_15A shows that a tracer dose of the cell targeting complex bound to the cells and that binding could be displaced by excess of unlabeled M6PHSA.
- PTX-cisULS-M6PHSA (1 mg/ml, 4h at 37°) by anti-HSA immunodetection, while PTX-HSA did not bind to the cells ( Figure 15B).
- binding of PTX-M6PHSA to target cells was mediated via the M6P homing ligands in the conjugates.
- Figure_16A shows that binding of RGDPEG-SB202190-cisULS-HSA to endothelial cells (HUVEC) could be displaced by free RGD-peptide, as well as by RGDPEG-HSA not equipped with SB202190. In contrast, SB202190- cisULS-HSA did not affect the interaction between complex and target cells.
- Figure 16B shows that accumulation of the complex increased in time when cells and compounds were incubated at 37°C, which indicated receptor mediated internalization of the complex. In a different experimental setup that allowd the calculation fo binding constants, we explored the affinity of RGD-equipped PTK787-cisULS- albumins.
- 125 I-labeled echistatin was used as a radioligand for ⁇ v63-integrin expressed on the surface of HUVEC.
- Competitive binding studies were performed by coincubating using confluent monolayers of HUVEC with the radiolabeled ligand and non-radiolabeled complexes. All RGD equipped conjugates completely displaced 125 I-echistatin, while conjugates modified with the control RAD peptide demonstrated no displacement ( Figure 17A-C).
- conjugation of PTK787-cisULS to the carrier did not hamper the interaction between homing ligand and target cells, since carrier with and without drug showed similar affinity.
- In vivo targeting studies encompassed studies in which drug levels in the target organ or other tissues or body fluids (serum, urine) were quantified by HPLC. Typically, drug levels were determined by HPLC after release of the drug from the targeting complex, or free drug levels reflecting drug released from the complexes were assayed. Furthermore, accumulation of cell targeting complexes in tissues or cell types was determined by immunohistochemical staining for the complex (anti-HSA or anti-LZM staining) or by detection of radiolabeled complexes ( 125 I-radiolabeled conjugates). Typical examples are shown in Figures 18-22.
- Rats were i.v. injected via the dorsal penis vein with tracer doses (106 cpm/rat) of either i25 i_p ⁇ X-eisULS-M6PHSA or 125 I-radiolabeled M6PHSA.
- tracer doses 106 cpm/rat
- blood samples were taken by heart puncture and the organs were excised, washed in saline, and weighed after which radioactivity was counted. Urine was recovered from the bladder and measured. The total radioactivity per organ was calculated and corrected for blood-derived radioactivity using BDL correction factors.
- Losartan-cisULS- M ⁇ PHSA was not detected in the lung (a), spleen (b), heart (c) or kidney (d) (magnification 4x) in rats treated with losartan-cisULS-M ⁇ PHSA, but was prominently detected in the liver within non-parenchymal cells of (e) (magnification 4x).
- Losartan-cisULS-M ⁇ PHSA co-localized with stellate cells in rat livers (arrows), as assessed with double immunostaining with anti-HSA and anti-desmin (f) (magnification 4Ox).
- liver tissue homogenates 0.3 g liver/ml of PBS, Turrax homogenization
- HPLC HPLC
- KSCN 8O 0 C 0.5M KSCN 8O 0 C
- losartan-cisULS- M6PHSA demonstrated a preferential liver distribution.
- drug levels in HSC are most likely much higher due to the cell-specific accumulation of the cell targeting complex and the fact that stellate cells constitute only a small fraction of the whole liver. Oral administered losartan does not show this preferential homing to HSC.
- PTKI-cisULS-M6PHSA 3.3 mg/kg, corresponding to 150 ⁇ g PTKI/kg.
- Control animals were injected with an equivalent volume of the vehicle (saline) Animals were sacrificed 2h post injection of the compounds, and organs were harvested and processed for immunohistochemical detection of the conjugate as described above for other drug-cisULS-M6PHSA conjugates.
- Rats were injected intravenously with a single dose of the SB202190- cisULS-lysozyme conjugate (16 mg/kg equivalent to 376 ⁇ g/kg of SB202190; dissolved in 5% glucose) via the penile vein. Animals were sacrificed at different time points between 1 and 72h after administration. Blood samples were collected by heart puncture and kidneys were isolated after flushing the organs gently with saline. Serum and organs were snap-frozen into liquid nitrogen immediately. Urine samples were collected using metabolic cages and combined with the urine collected from urinary bladder after sacrificing the animals. Kidneys were weighed, homogenized (1:3 w/v in PBS, Turrax homogenization) and then stored at -80°C.
- SB202190-cisULS-LZM accumulated efficiently in the kidneys within 1 h following the intravenous injection, amounting to a total of 20% of the injected dose (Figure 20B).
- Figure 20B we observed continuous levels of both free drug and bound drug during a three-day period after a single dose. This profile can be explained by the renal accumulation of the product, which subsequently forms a depot that generates free drug by slow drug release from the linker.
- after administration of 5 mg/kg of free SB202190 only 0.2% distributed to the kidney at 4h after administration [4] .
- This difference between free drug and SB202190-cisULS-LZM clearly illustrates the potential of the developed cell targeting complex in providing selective enrichment of drugs in specific tissues.
- Figure_21 shows the results obtained with TKI-cisULS-LZM.
- Panel A serum disappearance
- panel B renal drug levels
- panel C cumulative excretion in urine .
- Symbols represent the %dose of TKI at each time point; the continuous line represents the pharmacokinetic data-fit curve (two- compartment model).
- Panel (D) represents the localization of the conjugate in tubular cells at 1 h by anti-LZM immunohistochemical analysis (magn. 20Ox).
- TKI-cisULS-LZM distributed rapidly and extensively to the kidneys and provided renal drug levels by local drug release in an analogous manner as observed for SB202190-cisULS-LZM.
- Cryostat sections or paraffin-embedded sections were processed for immunohistochemical staining according to standard procedures, and positively stained areas were quantified by morphometric analysis.
- the degree of hepatic fibrosis was estimated as the percentage of area of each section stained positive with picro Sirius Red.
- the amount of fibrogenic myofibroblasts was estimated by measuring the percentage of area positively stained for ⁇ SMA.
- the amount of infiltrated inflammatory cells was estimated by quantification of anti-CD43 immunostaining.
- the cumulated data together demonstrate that this type of cell targeting complexes can intervene in liver fibrosis, and even reverse fibrotic processes. Furthermore, the effects can be obtained at considerable lower doses of drug as reported for the non-delivered drugs.
- Figure_23 Effect of losartan-cisULS-M6PHSA at hepatic fibrosis in BDL rats (Sirius Red staining in paraffin embedded sections and quantification). Severe bridging was observed in rats receiving saline (A), M6PHSA (B) and oral losartan (D). However, rats treated with losartan-cisULS-M6PHSA (C) showed fewer areas with collagen accumulation (magnification 4x). (E):
- Fig ⁇ re_24 Effect of losartan-cisULS-M6PHSA at hepatic fibrosis in CCl 4 rats (Sirius Red staining in paraffin embedded sections and quantification).
- CCL4 rats were treated with: A. Saline, B. M6PHSA, C. losartan-cisULS-
- Figure_25 Effect of different treatments on the accumulation of myofibroblasts and activated hepatic stellate cells, as assessed by expression of ⁇ SMA.
- BDL rats receiving saline (A), M6PHSA (B) or oral losartan (D) showed a marked accumulation of ⁇ SMA-positive cells, which co-localized with areas with active fibrogenesis.
- rats treated with losartan-cisULS-M6PHSA (C) showed a marked reduction in ⁇ SMA-positive cells (magnification 4x).
- E High magnification (40Ox) photomicrograph of a liver from a bile duct ligated rat treated with saline. ⁇ SMA staining was detected in cells located in the sinusoids corresponding to activated hepatic stellate cells (upper arrow) as well as in myofibroblasts around proliferating bile ducts (lower arrow).
- Figuje_26 Effect of different treatments on the infiltration of inflammatory cells in the hepatic parenchyma, as assessed by CD43 staining.
- BDL rats receiving saline (A) or M6PHSA (B) showed intense infiltration by CD43-positive cells (brown staining).
- Treatment with losartan-ULS-M6PHSA (C), and in a lesser extent losartan (D) reduced the number of CD43 infiltrating leukocytes (magnification 4x).
- E Quantification of the number of positive cells in 20 randomly chosen high power fields. *P ⁇ 0.05 vs saline and M6PHSA.
- Figure_27 Effect of PTKI-cisULS-M6PHSA on the deposition of collagen in the liver, as assessed by Sirius Red staining.
- A Quantification of the area with Sirius Red staining in rat liver specimens *P ⁇ 0.05 vs BDL saline control.
- Rats receiving saline showed a marked deposition of collagen, which co-localized with areas with active fibrogenesis.
- Rats treated with PTKI-cisULS-M6PHSA showed attenuated liver fibrosis development at day 11 and 12 post BDL (i.e. 24h and 48 after administration, respectively).
- Figure_28 Effect of PTKI-cisULS-M6PHSA on the accumulation of myofibroblasts and activated HSC, as assessed by expression of ⁇ SMA.
- SB202190-cisULS-LZM In order to detect potential platinum -related toxicity of kidney directed cell targeting complexes, we evaluated SB202190-cisULS-LZM in healthy rats. Male Wistar rats were treated with SB202190-cisULS-LZM as described above and compared to untreated animals and to animals treated with a low dose of cisplatin (3 mg/kg, i.v.) for 24 h. The dose of cisplatin used is however 8-fold higher than the amount of platinum in the SB202190-cisULS-LZM conjugate. To examine the effect on renal function, serum and urine creatinine levels were determined and creatinine clearances were calculated.
- Table 1 Pharmacological evaluation of SB202190-cisULS-LZM in normal rats. Comparison of renal function parameters, induction of apoptosis and renal platinum content.
- Urinary protein 19.16 ⁇ 1.3 29.6 ⁇ 2.0tt 23 ⁇ 3.6 levels (mg/d)
- the differences between cisplatin and SB-ULS-LZM groups are *p,0.05, **p,0.01.
- the differences versus untreated groups are tp,0.05, ++p ⁇ 0.01. N.D., not detectable.
- kidney directed cell targeting complexes The potential antifibrotic and anti-inflammatory activity of kidney directed cell targeting complexes was evaluated in two different models of renal disease, the unilateral ischemia/reperfusion injury (IfR) model and the unilateral ureteral obstruction (UUO) model.
- IfR unilateral ischemia/reperfusion injury
- UUO unilateral ureteral obstruction
- Kidneys were isolated after gently flushing the organs with saline and preserved in 4 % formalin for preparation of paraffin embedded sections, or frozen in ice-cold isopentane for preparation of cryosections. Immunostainings were performed according to generally established methods and quantified by morphonietric analysis or by semi- quantitative scoring a blind manner by two independent observers.
- Results obtained with SB202190-cisULS-LZM are shown in Figure 29.
- SB202190-cisULS-LZM was dissolved in 5 % glucose whereas SB202190 was dissolved in 20 % hydroxypropyl- ⁇ -cyclodextrin solution with 5 % DMSO.
- Anti-p-p38 imniunohistochemical stainings were performed on paraffin embedded sections.
- ⁇ SMA stainings were performed on cryostat sections. Vehicle treated I/R rats had dilated and damaged tubules that strongly showed p-p38 positive cells (panel A, grade +++) in both renal cortex and medulla. Treatment with SB202190-ULS-LZM reduced the number of p-p38 positive cells in the medulla (panel B, grade +) but no reduction was found in SB202190 treated animals (C, grade +++). Moreover, we found that after 4 days of I/R injury, SMA expression was highly increased in the tubulointerstitial space of the renal cortex (panel D, grade +++). A single dose of SB202190-ULS-LZM conjugate reduced SMA expression (panel E, grade ++) whereas non-targeted SB202190 did not affect the expression of SMA (panel F, grade +++).
- Figure_30 shows the results obtained after treatment of I/R rats with losartan-cisULS-LZM.
- Animals that were subjected to I/R procedure as described above were treated with four doses of losartan-cisULS-LZM (20 mg/kg/day, equivalent to 520 ⁇ g losartan/kg/day).
- the first dose was administered 2h before infliction of I/R damage and animals were sacrificed 24h after the last dose.
- To detect the number of infiltrated macrophages paraffin-embedded kidney sections were incubated with an antibody against the rat macrophage marker ED-I. The extent of interstitial macrophage influx was determined by computerized morphometry.
- the amount of brown precipitate was measured and represented as either number of macrophages in the selected area. All morphometric measurements were performed by a blinded observer. As can be observed, treatment with losartan-cisULS-LZM reduced the number of infiltrated macrophages.
- a third cell targeting complex evaluated in the unilateral I/R model is the Y27632-cisULS-LZM conjugate. Similar to losartan-cisULS-LZM, I/R animals were treated with four intravenous doses of the product (20 mg/kg of Y27632-cisULS-LZM equivalent to 555 ⁇ g/kg of Y27632, dissolved in 5% glucose).
- MCP-I monocyte chemoattractant protein-1
- TCP-I monocyte chemoattractant protein-1
- TIMP-I tissue inhibitor of metalloproteinase-1
- procollagen-I ⁇ l 5'-AGC CTG AGC CAG CAG ATT GA- 3' and 5'-CCA GGT TGC AGC CTT GGT TA-3', 145 bp
- alpha smooth muscle actin ⁇ -SMA; 5'-GAC ACC AGG
- TKI-cisULS-LZM The efficacy of TKI-cisULS-LZM was studied after a single dose of the compound in the UUO model of renal fibrosis.
- Animals were divided into 4 groups: normal rats, fibrotic control animals (vehicle, 5% glucose), TKI-LZM (25 mg/kg equiv. to 630 ⁇ g/kg TKI) and free, unconjugated TKI (630 ⁇ g/kg).
- TKI was dissolved in 20 % hydroxylpropyl- ⁇ -cyclodextrin in water with 5 % DMSO, whereas TKI-LZM was dissolved in 5 % glucose.
- kidneys were injected intravenously with either of these compounds 2h before the uretheral obstruction.
- Left kidneys and ureter were exposed via a flank-incision under isoflurane anesthesia after which the ureter was ligated at three sites with 4-0 silk near the hilum.
- animals were sacrificed under anesthesia and kidneys were gently flushed and harvested.
- Kidney cortex pieces were snap-frozen to isolate RNA as described above. Kidney pieces were fixed in 4 % formalin solution in PBS to make paraffin-embedded sections for anti- ⁇ -SMA and ED-I immunohistochemical staining and morphometric analysis. Results of the study are shown in Figure 32.
- TKI-cisULS-LZM Treatment with TKI-cisULS-LZM substantially reduced the MCP-I gene expression (panel A). In contrast, a single dose of free TKI did not lower the expressions of MCP-I. Immunohistochemical analyses confirmed the gene-expression data. In line with the lowered production of MCP-I, which is a chemoattractant for macrophages, we also detected significant reduced levels of infiltrated macrophages upon TKI-LZM treatment (ED-I immunostaining, panel B). However, in contrast to the gene expression study, we also found a reduction of ED-I immunostaining with free TKI.
- fibrosis marker ⁇ -SMA was also significantly decreased by TKI-LZM or TKI treatments, which indicates potential antifibrotic activity of TKI and TKI-LZM (panel C). These data demonstrate the potential antifibrotic activity of TKI-cisULS-LZM in renal fibrosis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/995,960 US20110104103A1 (en) | 2005-07-20 | 2006-07-20 | Method of conjugating therapeutic compounds to cell targeting devices via metal complexes |
JP2008522722A JP5178513B2 (en) | 2005-07-20 | 2006-07-20 | Method for binding therapeutic compounds to cell targeting devices via metal complexes |
CA002616116A CA2616116A1 (en) | 2005-07-20 | 2006-07-20 | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
EP06783853A EP1907011A2 (en) | 2005-07-20 | 2006-07-20 | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
AU2006270566A AU2006270566B2 (en) | 2005-07-20 | 2006-07-20 | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05076682.3 | 2005-07-20 | ||
EP05076682A EP1745802A1 (en) | 2005-07-20 | 2005-07-20 | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007011217A2 true WO2007011217A2 (en) | 2007-01-25 |
WO2007011217A3 WO2007011217A3 (en) | 2007-11-22 |
Family
ID=36228717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2006/000383 WO2007011217A2 (en) | 2005-07-20 | 2006-07-20 | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110104103A1 (en) |
EP (2) | EP1745802A1 (en) |
JP (1) | JP5178513B2 (en) |
AU (1) | AU2006270566B2 (en) |
CA (1) | CA2616116A1 (en) |
WO (1) | WO2007011217A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009065292A1 (en) * | 2007-10-23 | 2009-05-28 | Nanjing University | Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
WO2013095132A1 (en) | 2011-12-22 | 2013-06-27 | Interna Technologies B.V. | Mirna for treating head and neck cancer |
WO2013103301A2 (en) | 2012-01-06 | 2013-07-11 | Linxis B.V. | Method for preparing cell targeting conjugates, and the complexes obtained |
CN103288968A (en) * | 2013-06-25 | 2013-09-11 | 上海同科生物科技有限公司 | An anti-tumor targeting complex and a preparation method and applications thereof |
WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
CN108273553A (en) * | 2017-12-25 | 2018-07-13 | 广东工业大学 | A kind of platinum catalyst of sulfur poisoning-resistant and preparation method thereof |
WO2019068766A1 (en) | 2017-10-03 | 2019-04-11 | Aptahem Ab | A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties |
WO2019086603A1 (en) | 2017-11-03 | 2019-05-09 | Interna Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
US11787865B2 (en) | 2018-12-19 | 2023-10-17 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2268320A4 (en) * | 2008-03-24 | 2014-10-01 | Univ Texas | Image-guided therapy of myocardial disease: composition, manufacturing and applications |
EP2938364A1 (en) * | 2012-12-28 | 2015-11-04 | Blend Therapeutics, Inc. | Targeted conjugates encapsulated in particles and formulations thereof |
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
NL2014423B1 (en) | 2015-03-09 | 2016-10-13 | Linxis B V | Method for removing weakly bound functional moieties from cell targeting conjugates. |
CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
CA3020339C (en) | 2016-04-07 | 2022-05-03 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
AU2017278573A1 (en) * | 2016-06-06 | 2019-01-03 | Linxis B.V. | Cell targeting conjugates |
NL2020121B1 (en) * | 2017-12-19 | 2019-06-26 | Linxis B V | Platinum-based functional moieties for preparing cell targeting conjugates |
CN108659096A (en) * | 2018-05-23 | 2018-10-16 | 西北工业大学 | A method of improving crystallization of protein success rate in crystallization plates surface grafting charge |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CN114681482B (en) * | 2021-08-30 | 2023-05-05 | 深圳大学 | Nanometer enzyme and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0742286A2 (en) * | 1995-05-08 | 1996-11-13 | Roche Diagnostics GmbH | Quantitative detection of nucleic acids |
US5714327A (en) * | 1990-07-19 | 1998-02-03 | Kreatech Diagnostics | Platinum-containing compounds, methods for their preparation and applications thereof |
EP0870770A1 (en) * | 1997-04-10 | 1998-10-14 | Kreatech Biotechnology B.V. | A trans-platinum based compound, a diagnostic kit comprising said compound and a method for labeling a bio-organic molecule wherein use is made of said compound |
WO2002013843A2 (en) * | 2000-08-17 | 2002-02-21 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
WO2002097439A2 (en) * | 2001-05-28 | 2002-12-05 | Kreatech Biotechnology B.V. | A differential labelling method |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4793986A (en) * | 1987-02-25 | 1988-12-27 | Johnson Matthey, Inc. | Macromolecular platinum antitumor compounds |
NZ307633A (en) | 1995-05-09 | 2000-01-28 | Kreatech Biotechnology Bv | Methods for the production of platinum-based linkers between labels and bio-organic molecules, for labelling bio-organic molecules, for detecting |
USRE40557E1 (en) | 1996-10-08 | 2008-10-28 | Kreatech Biotechnology B.V. | Methods for labeling nucleotides, labeled nucleotides and useful intermediates |
JP2001302550A (en) * | 2000-02-18 | 2001-10-31 | Kanagawa Acad Of Sci & Technol | Pharmaceutical composition, reagent and method for delivering pharmaceutically active ingredient or labeled substance into brain |
US20030049203A1 (en) * | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
EP1669760A1 (en) | 2004-12-08 | 2006-06-14 | Kreatech Biotechnology B.V. | Labeled transition metal complexes |
SI2097111T1 (en) * | 2006-11-08 | 2016-02-29 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
WO2008073660A1 (en) * | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
-
2005
- 2005-07-20 EP EP05076682A patent/EP1745802A1/en not_active Withdrawn
-
2006
- 2006-07-20 WO PCT/NL2006/000383 patent/WO2007011217A2/en active Application Filing
- 2006-07-20 CA CA002616116A patent/CA2616116A1/en not_active Abandoned
- 2006-07-20 JP JP2008522722A patent/JP5178513B2/en active Active
- 2006-07-20 AU AU2006270566A patent/AU2006270566B2/en not_active Ceased
- 2006-07-20 US US11/995,960 patent/US20110104103A1/en not_active Abandoned
- 2006-07-20 EP EP06783853A patent/EP1907011A2/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714327A (en) * | 1990-07-19 | 1998-02-03 | Kreatech Diagnostics | Platinum-containing compounds, methods for their preparation and applications thereof |
EP0742286A2 (en) * | 1995-05-08 | 1996-11-13 | Roche Diagnostics GmbH | Quantitative detection of nucleic acids |
EP0870770A1 (en) * | 1997-04-10 | 1998-10-14 | Kreatech Biotechnology B.V. | A trans-platinum based compound, a diagnostic kit comprising said compound and a method for labeling a bio-organic molecule wherein use is made of said compound |
WO2002013843A2 (en) * | 2000-08-17 | 2002-02-21 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
WO2002097439A2 (en) * | 2001-05-28 | 2002-12-05 | Kreatech Biotechnology B.V. | A differential labelling method |
Non-Patent Citations (13)
Title |
---|
BATALLER R ET AL: "Liver fibrosis" JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 2, February 2005 (2005-02), pages 209-218, XP002450194 ISSN: 0021-9738 * |
CASTAÑO GUSTAVO ET AL: "A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients." ANNALS OF HEPATOLOGY : OFFICIAL JOURNAL OF THE MEXICAN ASSOCIATION OF HEPATOLOGY, vol. 2, no. 1, January 2003 (2003-01), pages 36-40, XP002450195 ISSN: 1665-2681 * |
GONZALO TERESA ET AL: "Short-term treatment with losartan targeted to activated stellate cells reduces advanced liver fibrogenesis: A new strategy to treat liver fibrosis" HEPATOLOGY, vol. 42, no. 4, Suppl. 1, October 2005 (2005-10), page 604A, ABSTRACT 1037, XP008083455 & 56TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; SAN FRANCISCO, CA, USA; NOVEMBER 11 -15, 2005 ISSN: 0270-9139 * |
GREUPINK RICK ET AL: "Hepatic stellate cell specific delivery of mycophenolic acid as a strategy to treat liver fibrosis." HEPATOLOGY, vol. 38, no. 4, Suppl. 1, October 2003 (2003-10), page 331A, ABSTRACT NO. 354, XP002380497 & 54TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES; BOSTON, MA, USA; OCTOBER 24-28, 2003 ISSN: 0270-9139 * |
KOK ROBBERT J ET AL: "Preparation and functional evaluation of RGD-modified proteins as alphavbeta3 integrin directed therapeutics" BIOCONJUGATE CHEMISTRY, vol. 13, no. 1, January 2002 (2002-01), pages 128-135, XP002380500 ISSN: 1043-1802 cited in the application * |
KOSTIC N M: "Transition-metal complexes as spectroscopic probes for selective covalent labeling and cross-linking of proteins." METHODS IN ENZYMOLOGY, vol. 226, 1993, pages 565-576, XP008063637 ISSN: 0076-6879 * |
LAZARO TERESA GONZALO ET AL: "Delivery of pentoxifylline to hepatic stellate cells as a new tool to attenuate liver fibrosis." HEPATOLOGY, vol. 40, no. 4, Suppl. 1, October 2004 (2004-10), pages 610A-611A, XP002380494 & 55TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES (AASLD); BOSTON, MA, USA; OCTOBER 29 -NOVEMBER 02, 2004 ISSN: 0270-9139 * |
PARFITT K (ED.): "Oxpentifylline" 1999, MARTINDALE : THE COMPLETE DRUG REFERENCE, 32TH EDITION, PAGE(S) 925-926 , PHARMACEUTICAL PRESSS, LONDON, GB , XP002433802 ISBN: 0-85369-429-X page 925, right-hand column, paragraph OXPENTIFYLLINE - page 926, middle column * |
PRAKASH JAI ET AL: "Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme" DRUG METABOLISM AND DISPOSITION, vol. 33, no. 5, May 2005 (2005-05), pages 683-688, XP002380499 ISSN: 0090-9556 cited in the application * |
SITZMANN J V ET AL: "Altered angiotensin-II receptors in human hepatocellular and hepatic metastatic colon cancers" ANNALS OF SURGERY, vol. 219, no. 5, 1994, pages 500-507, XP002450196 ISSN: 0003-4932 * |
VAN GIJLSWIJK, ROB P. M. ET AL: "Use of horseradish peroxidase- and fluorescein-modified cisplatin derivatives for simultaneous labeling of nucleic acids and proteins" CLINICAL CHEMISTRY, vol. 48, no. 8, 2002, pages 1352-1359, XP002380498 ISSN: 0009-9147 * |
YE ZHAOYANG ET AL: "Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells" BIOCHEMISTRY, vol. 44, no. 11, March 2005 (2005-03), pages 4466-4476, XP002380495 ISSN: 0006-2960 * |
ZHANG JIAN ET AL: "Synthesis of a targeting drug for antifibrosis of liver; A conjugate for delivering glycyrrhetin to hepatic stellate cells." GLYCOCONJUGATE JOURNAL, vol. 19, no. 6, July 2002 (2002-07), pages 423-429, XP002380496 ISSN: 0282-0080 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9340596B2 (en) | 2007-10-23 | 2016-05-17 | Nanjing University | Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof |
WO2009065292A1 (en) * | 2007-10-23 | 2009-05-28 | Nanjing University | Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
EP3214174A1 (en) | 2010-03-04 | 2017-09-06 | InteRNA Technologies B.V. | A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt |
WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
EP3369817A1 (en) | 2010-07-06 | 2018-09-05 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
WO2012096573A1 (en) | 2011-01-11 | 2012-07-19 | Interna Technologies B.V. | Mirna for treating diseases and conditions associated with neo-angiogenesis |
WO2013095132A1 (en) | 2011-12-22 | 2013-06-27 | Interna Technologies B.V. | Mirna for treating head and neck cancer |
WO2013103301A3 (en) * | 2012-01-06 | 2013-09-12 | Linxis B.V. | Method for preparing cell targeting conjugates, and the complexes obtained |
WO2013103301A2 (en) | 2012-01-06 | 2013-07-11 | Linxis B.V. | Method for preparing cell targeting conjugates, and the complexes obtained |
US10668162B2 (en) | 2012-01-06 | 2020-06-02 | Linxis B.V. | Method for preparing cell targeting conjugates, and the complexes obtained |
WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
EP3800256A1 (en) | 2012-11-06 | 2021-04-07 | InteRNA Technologies B.V. | Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway |
CN103288968A (en) * | 2013-06-25 | 2013-09-11 | 上海同科生物科技有限公司 | An anti-tumor targeting complex and a preparation method and applications thereof |
WO2019068766A1 (en) | 2017-10-03 | 2019-04-11 | Aptahem Ab | A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties |
WO2019086603A1 (en) | 2017-11-03 | 2019-05-09 | Interna Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
CN108273553A (en) * | 2017-12-25 | 2018-07-13 | 广东工业大学 | A kind of platinum catalyst of sulfur poisoning-resistant and preparation method thereof |
US11787865B2 (en) | 2018-12-19 | 2023-10-17 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
EP1907011A2 (en) | 2008-04-09 |
CA2616116A1 (en) | 2007-01-25 |
WO2007011217A3 (en) | 2007-11-22 |
JP2009501791A (en) | 2009-01-22 |
EP1745802A1 (en) | 2007-01-24 |
JP5178513B2 (en) | 2013-04-10 |
AU2006270566B2 (en) | 2012-05-31 |
US20110104103A1 (en) | 2011-05-05 |
AU2006270566A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006270566B2 (en) | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes | |
US6709679B2 (en) | Antineoplastic conjugates of transferin, albumin and polyethylene glycol | |
US6436912B1 (en) | Drug complexes | |
US6291671B1 (en) | Process for producing drug complexes | |
ES2364987T3 (en) | COPOLYMER OF BLOCKS FOR DRUG CONJUGATES AND THEIR PHARMACEUTICAL COMPOSITIONS. | |
AU2006200363B2 (en) | Glycopeptide compositions | |
AU4094300A (en) | Amplification of folate-mediated targeting to tumor cells using polymers | |
KR20150104092A (en) | Conjugates for treating diseases caused by psma expressing cells | |
JP2006523237A (en) | PI-3 kinase inhibitor prodrug | |
JP2003506319A (en) | Vitamin-related dual targeting therapy | |
US20240148916A1 (en) | Bivalent fibroblast activation protein ligands for targeted delivery applications | |
AU2020253385A1 (en) | Hsp90-binding conjugates and formulations thereof | |
Shi et al. | Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys | |
US20040176270A1 (en) | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | |
CA3094719A1 (en) | Hsp90-targeting conjugates and formulations thereof | |
WO2023122599A1 (en) | Glycosylated dendrimers for targeted intracellular delivery | |
NL2020121B1 (en) | Platinum-based functional moieties for preparing cell targeting conjugates | |
TW202313118A (en) | Dendrimer conjugates and methods of use thereof | |
EP4322961A1 (en) | Dendrimer-glutamine antagonist conjugates and methods of use thereof | |
JP2023540138A (en) | Galactosylated dendrimers for targeted intracellular delivery to hepatocytes | |
KR20030024800A (en) | Pharmaceutically active compound | |
Haverdings et al. | Drug targeting to the kidney: the low-molecular-weight protein approach | |
AU2004201277A1 (en) | Amplification of folate-mediated targeting to tumor cells using polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006270566 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008522722 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2616116 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006270566 Country of ref document: AU Date of ref document: 20060720 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2006783853 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006783853 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11995960 Country of ref document: US |